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Abstract
We first show theoretically and in simulation how power varies as a function of SNP correlation
structure with currently-implemented gene-based testing methods. We propose alternative testing
methods whose power does not vary with the correlation structure. We then propose hypothesis
tests for detecting prevalence-incidence bias in case-control studies, a bias perhaps overrepresented
in GWAS due to currently used study designs. Lastly, we hypothesize how different incentive struc-
tures used to keep clinical trial participants in studies may interact with a background of dependent
censoring and result in variation in the bias of the Kaplan-Meier survival curve estimator.
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Properties of permutation tests and alternative methods for gene-based testing
David M. Swanson⇤, Deborah Blacker, Taofik Al-Chawa,
Kerstin U. Ludwig, Elisabeth Mangold, Christoph Lange
Abstract
The advent of genome-wide association studies has led to many novel disease-SNP associations, open-
ing the door to focused study on their biological underpinnings. Because of the importance of analyzing
these associations, numerous statistical methods have been devoted to them. However, fewer meth-
ods have attempted to associate entire genes or genomic regions with outcomes, which is potentially
more useful knowledge from a biological perspective and those methods currently implemented are of-
ten permutation-based. One property of some permutation-based tests is that their power varies as a
function of whether significant markers are in regions of linkage disequilibrium (LD) or not, which we
show from a theoretical perspective. We therefore develop two methods for quantifying the degree of
association between a genomic region and outcome, both of whose power does not vary as a function of
LD structure. One method uses dimension reduction to “filter” redundant information when significant
LD exists in the region, while the other controls for LD by scaling marker Z-statistics using knowledge
of the correlation matrix of markers. One advantage of the former test is power gains due to dimension
reduction, while an advantage of the latter test is that the full data set is not needed, but just sum-
mary Z-statistics from univariate regressions of markers and the underlying correlation structure of those
markers which are publicly available in some cases. We show how to modify the latter test when the
correlation structure of markers is imperfectly known in order to protect the type 1 error rate. We apply
these methods to sequence data of oral cleft and compare our results to previously proposed gene tests,
in particular permutation-based ones. We find a significant association in the sequence data between the
8q24 region and oral cleft using our dimension reduction approach and a borderline significant associa-
tion using the summary-statistic based approach. We also implement the summary-statistic test using
Z-statistics from an already-published GWAS of Chronic Obstructive Pulmonary Disorder (COPD) and
correlation structure obtained from HapMap. We experiment with the modification of this test because
the correlation structure is assumed imperfectly known.Dimension reduction; Eigenvector; Gene-based
testing; Permutation tests.
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1 Introduction
The focus in genetic association studies has been on uncovering loci that are risk factors for an outcome,
be it binary or continuous, or markers in linkage disequilibrium (LD) with those causal loci. Increasingly,
however, gene-based tests are coming to the forefront, especially as sequencing technologies mature and grow
cheaper [8, 3, 14]. Gene-based tests are useful to provide insight into whether a region of the genome has a
significant association with some outcome and for inter-gene significance comparisons, despite di↵erences in
the size of genes [6, 7]. Development of such tests is di cult, however, as markers are usually correlated with
one another and have highly variable minor allele frequencies [15]. As a result, tests have often been born
more out of practicality or computational ease. Some gene-based tests take the smallest p-value over all the
markers in the region. Others, such as that implemented in PLINK, take a more sophisticated approach,
converting p-values of markers to  21 test statistics, averaging those tests statistics, then comparing it to a
null distribution generated from permutations of the outcome under the null [12, 8]. Liu et al. (2010) use
a similar, though more e cient method, in which they again convert marker p-values to  21 test statistics,
take the sum of those test statistics, then generate a null distribution by sampling from sums of correlated
 21 random variables. Both approaches are intuitive and valuable ways to assess gene significance, though in
both cases the power for detection of a gene becomes not only a function of the e↵ect size of the individual
markers, but the degree to which markers are in LD with one another. For example, assuming only one
marker in the region has a truly non-zero e↵ect size, power for detecting that e↵ect will be higher if the
marker is in high LD with other markers than if it is independent of them. Moskvina et al. (2012) make
this same observation, having noticed that the significance of regions they tested changed according to how
much they pruned markers in high LD with one another [10].
One way to think about why this phenomenon occurs is that, rather than transforming the test statistic
so that markers highly correlated with one another “mean less” because they do not contribute independent
information, they transform the null distribution for certain markers under the null to “mean more.” As a
result, the type 1 error is maintained, but power varies as a function of the correlation between the marker
and surrounding markers. Intuitively, this is not a desirable property because it will lead to a systematic
under-detection of those loci that happen to be independent of proximal markers even though they are
inherently no less important in predicting the outcome. This issue becomes particularly problematic for
sequence data since there would generally be even more correlation. However, the issue is a zero-sum trade-
o↵; what results in less power for detection of single nucleotide polymorphisms (SNPs) in low LD translates
to more power for detection of SNPs in high LD. Though, if there is an underlying common function or
characteristic of those genomic regions whose significant SNPs are not in high LD, perhaps due to when
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they first occurred in evolutionary history, such regions will likely be missed in association analyses so that
potentially key regions will not be studied in greater depth. As a result of this shortcoming, which may
be more or less important depending on the specific LD structure of the genomic region under study, we
propose two methods, one of which transforms summary Z-statistics from univariate regressions of markers
so that it follows a standard parametric distribution under the null hypothesis and power does not vary with
the LD structure, and the second of which uses an eigendecomposition of the information matrix to find the
“e↵ective” amount of information in the region and increases power by performing a more parsimonious test.
If the information matrix is evaluated under the null, this latter test is essentially a dimension-reduced score
test analogue to a method described in [3, 14], which finds the principal components of the data matrix.
Specifically, for the first approach we propose, we find Z-statistics associated with each marker in our region
and the correlation matrix of the markers and perform a  2 test, an approach similar to that proposed by
Yang et al. (2012). In case the correlation matrix is imperfectly known, we propose a modification of this
test that adjusts the correlation structure to protect the type 1 error. In the latter approach, we calculate
the eigenvectors associated with the information matrix to obtain a most powerful linear combination of
the scores, on which we again perform a  2 test after having normalized by the variance of the loadings.
Moskvina et al. (2012) also propose solutions, one of which is based on Hotelling’s T 2 test, while another is
based on multivariate logistic regression, though concludes that both perform similarly. We compare these
various approaches under di↵erent structures of LD and e↵ect size. We apply our methods to a case-control
sequence data set of oral cleft and an already-published GWAS study of Chronic Obstructive Pulmonary
Disorder (COPD) [11].
2 Methods
2.1 Description of permutation tests
First we show how power di↵ers for permutation-based gene tests as a function of linkage disequilibrium from
a theoretical perspective. When we refer to permutation-based gene tests, we mean gene-based tests in which
the sum of the  2 statistics for markers is taken and then an empirical p-value is calculated by permuting
case-control status to generate a null distribution. By Imhof (1961), in connection with Liu et al. (2010),
we know that the null distribution of the permutation-based test is
Pq
i=1  i 
2
1, where  
2
1 is a chi-squared
random variable on 1 d.f.,  i is the ith eigenvalue of ⌃, the q ⇥ q correlation matrix of the SNPs comprising
the gene to be tested. Under the alternative, the distribution is approximately
Pq
i=1  i 
2
1( 
2
i ), where the
non-centrality parameter  i is calculated  i = vti · µ/
p
 i, where vi is the eigen vector of ⌃ corresponding
to  i, and µ is the q-dimensional mean of the multivariate normal distribution of Z-statistics calculated
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for univariate regressions of each SNP. µ is a function of the power for detection of each SNP in the gene.
The distribution under the alternative is approximately
Pq
i=1  i 
2
1( 
2
i ), rather than exactly, because the
correlation matrix of marker Z-statistics coming from univariate regressions diverges from the correlation
structure of the covariates when under the alternative. However, so long as there is not significant variation
between observations in the true probability of being a case, this divergence will not be relevant. Since the
relative risk of disease conferred by most minor alleles is small, it is likely that the approximation is valid in
most studies.
Suppose there is a single causal SNP X1 and, without loss of generality, it is the first entry in the (q+2)-
marker gene and q other SNPs, Zi, 1  i  q, are correlated with it but do not cause the outcome. Also
assume that the correlation coe cient between X1 and Zi is ⇢i, and the last SNP, X2, is uncorrelated with
X1 and does not cause the outcome. The first entry of µ, which represents the mean of the Z-statistic for
X1, can be written k1 · pn for some number k1 where n is the sample size. Since the asymptotic relative
e ciency for using Zi rather than X1 is ⇢2i , the i
th entry of µ, that associated with Zi, can be written
k1 · ⇢i ·pn [13, 5]. The entries of µ1, the (q + 2)-dimensional mean of the Z-statistics corresponding to the
permutation-based gene test when the causal SNP is X1, are
µ1
T = (k1
p
n, k1 · ⇢1
p
n, k1 · ⇢2
p
n, . . . , k1 · ⇢q
p
n, 0).
In contrast, suppose that the correlation structure among SNPs is the same, that is, Cor(X1, Zi) = ⇢i for
1  i  q, but X1 does not cause the outcome, and instead X2, the SNP uncorrelated with all other (q + 1)
markers, causes the outcome and to the same degree as X1 did so in the previous scenario. Then µ2, the
(q + 2)-dimensional mean in this case is
µ2
T = (0, 0, 0, . . . , 0, k1
p
n).
If Q ⌘ Pqi=1  i 21( 2i ), the power of an size ↵ (i.e., type 1 error rate) permutation-based gene test is
P (Q > c⇤), where c⇤ is the (1   ↵) quantile of the random variable Pqi=1  i 21. The intuition behind the
power gains for causal SNPs in regions of LD is that the non-centrality parameters  i will generally be larger
when the causal SNP is in a region of LD than when it is not. Providing greater rigor than this intuition
is di cult because the calculation of  i for all 1  i  (q + 2), even in the simple case of ⇢i = ⇢j for all
1  i  q, can be complicated. However, sampling from the appropriate distributions demonstrates that
there is greater power to detect a gene-outcome association when the causal SNP is in a region of LD. Figure
1 shows that under the alternative of gene-outcome association and for a fixed e↵ect size and ⇢i = ⇢j = ⇢
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for 1  i  q, i.e., the (q + 2)⇥ (q + 2) correlation matrix ⌃ is
⌃ =
2666666666666664
1 ⇢ ⇢ . . . ⇢ 0
⇢ 1 ⇢ . . . ⇢ 0
⇢ ⇢ 1 . . . ⇢ 0
...
...
...
. . .
...
...
⇢ ⇢ ⇢ . . . 1 0
0 0 0 . . . 0 1
3777777777777775
,
the distribution of the test statistic Q when the causal SNP in the gene is in a region of LD is stochastically
greater than the distribution when the causal SNP in the gene is not in a region of LD. As a result, power is
greater to detect a gene whose causal SNP is in a region of LD for a test of any size ↵ in a permutation-based
gene test. Figure 1 was generated assuming a gene consisting of 7 markers, where 6 markers were correlated
with coe cient ⇢, shown for values 0.2, 0.5, and 0.8 in the figure, with the causal SNP in the LD block
(y-axis) versus not in the LD block (x-axis). While the example may seem contrived, if we consider q = 10
so that our gene consists of 12 SNPs in total, the correlation structure in this example is similar to choosing
the first 12 SNPs of BRCA1 [2], in which case ⇢ ⇡ 0.96, and where the last row and column above would be
approximately 0.24 rather than 0.
Figures 2 and 3 demonstrate from a graphical perspective how permutation-based gene tests can have vari-
able power as the LD structure changes. The figures illustrate that there is more power for the permutation-
based gene test when causal SNPs are in high LD blocks as compared to causal SNPs in low LD blocks.
Additionally, if a causal SNP is not in LD with other SNPs, but large LD blocks exist in the gene, power
for the permutation-based gene test decreases as the size of the block increases. Data were generated with
a minor allele frequency of all SNPs of approximately 0.3 with Hardy-Weinberg equilibrium assumed, and,
within the LD block, correlation between SNPs was approximately 0.65, whereas SNPs not in the LD block
were independent of one another. The gene consisted of 20 SNPs, and there were 600 subjects with an equal
number of cases and controls. Power calculations were based on 1000 iterations at each e↵ect size (Figure 2)
or LD block size (Figure 3). We calculated power at 18 di↵erent e↵ect sizes (Figure 2), with the e↵ect size
ranging from a log OR of 0 to 1.2, and 20 di↵erent LD block sizes (Figure 3), with the LD block size ranging
from 1 SNP to 20 SNPs. So when the size was 20 SNPs, the LD block was the entirety of our hypothetical
gene (Figure 3). Binary outcomes were generated assuming a logistic regression model.
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Figure 1: The higher the correlation in the LD block containing the causal SNP, the more power relative to
the causal SNP not in the LD block using the permutation-based test.
Figure 2: There is more power to detect a SNP in high
LD with other, non-causal SNPs, than a SNP in low
LD for an identical e↵ect size.
Figure 3: For a constant e↵ect size, size of the LD
block in which the causal SNP is located is related to
the power for detection.
3 Summary statistic based test
We first describe a simple solution to the problem of how LD structure can a↵ect the power to detect genomic
regions in which there are significant SNPs. Our solution is based on the Z-statistics associated with each
marker and the correlation matrix of the SNPs. Since we propose this test as one that can be used without
a full data set, we propose a modification of it in case the true correlation structure is not perfectly known
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or it is believed that study participants are not reflective of the population from which the correlations of
SNPs are calculated (such as with HapMap reference panels).
3.1 Description
One solution to the problem of under-detection of SNPs in low LD posed by permutation tests is transfor-
mation of the gene-based test statistic so that under the null it follows a standard parametric distribution,
rather than creating a non-standard null distribution through permutations. One way to accomplish this
task, and one in which it is unnecessary to reanalyze data, is to perform a joint test on the Z-statistics
coming from a univariate regression model for each marker. It is a an approach similar to that described
by Yang et al. (2012), though uses summary statistics directly rather than estimated model coe cients.
Since the estimated covariance structure of these statistics under the null is the correlation of the markers
themselves [1], one can use the data to estimate the covariation of the Z-statistics or an online database
of LD or correlation structure of SNPs. We show the result in the context of a logistic regression model
as is generally used in case-control studies, though the result is identical for other parametric models. The
intuition behind this result is that if two markers are highly correlated, then when by chance under the null,
one marker is significant (or insignificant), the other marker will similarly be significant (or insignificant).
However, if two markers are not correlated, then the chance significance or insignificance of one marker will
not inform the significance of the other marker. And since Z-statistics have variance 1 by definition, their
covariance matrix is identical to their correlation matrix. Thus, supposing we have q markers, which, from
previous studies, are known to have Z-statistics of Z = (Z1, . . . , Zq)T , and which have correlation structure
V, then under the null hypothesis of no marker being associated with the outcome, T ⌘ ZTV  1Z ⇠ X2q .
One then rejects the null of no association between the region composing the q markers and the outcome for
an extreme value of the test statistic T using a pre-determined ↵ level.
If one is not confident that V accurately reflects the covariance of the SNPs in the data matrix and
therefore Z under the null hypothesis, it is possible to construct a more conservative test by shrinking the
o↵-diagonal elements of V towards 0. Thus, if V is an estimate of the covariance of the SNPs, one can
compute V ⇤  ⌘  V + (1   )Iq, where Iq is a q ⇥ q identity matrix and 0     1.
Again using [4], if Z ⇠ MVN(0, V ) but we use V ⇤  as an estimate of the correlation structure in the
gene based test, then ZTV ⇤ 1  Z ⇠
Pq
i=1  i ·  21 where q is the dimension of vector Z, and where  i is the
ith eigenvalue of VV⇤ 1  . By construction of V ⇤ 1  ,
Pq
i=1  i < dim(Z) for 0 <   < 1, where dim(·) the
dimension of the vector argument. This fact in itself does not not necessarily imply a more conservative test
for all size ↵ tests because when eigen values are not equal to one another as is the case for the decomposition
of VV⇤ 1  with V 6= V⇤ 1  ,
Pk
i=1  i < dim(Z) can be true, but Z
TV⇤ 1  Z is not stochastically less than
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 2dim(Z), the null distribution of the test statistic when the correlation structure is correctly known. However,
for modest values of   (i.e., 0.8-1.0, where 1.0 corresponds to no transformation), the test using the adjusted
correlation matrix will generally be more conservative. It is di cult to obtain simple solutions for how much
conservative a test will be using this modification since it will depend on the quantile corresponding to the
intended type 1 error and the specific VV⇤ 1  . Thus, to give a practical sense of useful values of  , we
borrowed a correlation structure of SNPs in the INS-IGF2 gene of Chromosome 11 from the CEU reference
panel in one case and the CHB+JPT reference panel in the other case [2]. If the true, underlying population
giving rise to the SNPs was more reflective of the CEU reference panel, but the analyst incorrectly guessed the
correlation structure to be that of the CHB+JPT reference panel when performing the summary statistic
gene-based test,the type 1 error rate for a nominal 0.05 size test would in fact be a highly inflated 0.61.
Similarly, if the true, underlying population giving rise to the SNPs was more reflective of the CHB+JPT
reference panel, but the analyst incorrectly guessed the correlation structure to be that of the CEU reference
panel for the summary statistic gene-based test, the type 1 error rate for a nominal 0.05 size test would be
0.69. If the type 1 error is inflated in one scenario, there is no implication that it will be deflated in the
’inverse’ scenario.
In the scenario where the underlying population was more reflective of the CEU panel, the type 1 error
using our modified summary statistic test with adjusted correlation matrix and  ’s of 0.9, 0.5, and 0.3 led
to reduced error rates of 0.36, 0.11, and 0.09, respectively, instead of 0.61. When the underlying population
was CHB+JPT, the type 1 error using our adjustment correlation matrix and  ’s of 0.9, 0.5, and 0.3 led to
reduced error rates of 0.45, 0.10, and 0.07, respectively, instead of 0.69. While in all cases, the nominal size
of the test is not quite achieved, type 1 error is greatly reduced, and in some cases will be achieved when
divergence between correlation structures of the true and hypothesized populations are not as great as that
in these scenarios. The greatest reduction in type 1 error occurs with initial deviation of   from 1; i.e., a
movement of   from 1 (indicating an unadjusted correlation matrix) to 0.9 will reduce type 1 error more
than a movement of 0.6 to 0.5. And, as mentioned, with very small values of  , there is not necessarily a
guarantee of continued reduction in type 1 error for some nominal ↵ level tests, nor should such   values be
used if indicative of no confidence in one’s estimated correlation matrix.
To simulate a less drastic divergence between true and estimated correlation matrices and assess error
rates and the proposed adjustment method in that context, we generated correlation matrices whose entries
were beta-distributed random variables with means corresponding to the entries in the CHB+JPT reference
panel and standard deviation approximately 0.03-0.04 (approximately because standard deviation is partly
a function of the mean). With a population whose underlying correlation structure was in truth reflective of
the CHB+JPT panel, but using the generated correlation matrices in our calculations of the test statistic, the
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average type 1 error rate was 0.19. Adjusting the generated correlation matrices according to our method
and with a   value of 0.95, the error rate was reduced to 0.05. Adjustment of the generated correlation
matrices with a   value of 0.90 led to a type 1 error rate of 0.03.
The summary statistic based test we have proposed is a viable way of performing gene-based testing
when one does not want power to vary as a function of the correlation structure of the SNPs composing
the gene. A weakness of such an approach is an inability to know the underlying correlation structure of
the SNPs used in the unvariate regression analyses givingn rise to the Z-statistics used in the summary
statistic test. We have shown that incorrect guesses of the underlying correlation structure can lead to a
significant increase in the type 1 error rate and therefore have proposed an adjustment method which can
lead to achievement of error rates in line with the nominal size of the test. However, since by supposition of
this setting the correlation structure of SNPs is never known, it is impossible to know the needed value of  .
As a result, it may be best to perform one’s summary statistic based test with   values ranging from 0.8-1.0
as a sensitivity analysis to see how one’s conclusions change based on di↵erent values. Values of   smaller
than 0.8 probably reflect little confidence in the estimated correlation structure, in which case feasibility of
the analysis in the first place should be reassessed.
Figure 4: Power comparison of Moskvina et al.’s
method with our summary statistic based method
when the causal SNP is in a block of high LD.
Figure 5: Power comparison of Moskvina et al.’s
method with our summary statistic based method
when the causal SNP is not in a block of high LD,
but there is an LD block elsewhere in the gene.
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Figure 6: A SNP in high LD with other, non-causal
SNPs, has no more power to be detected with the sum-
mary statistic test than a SNP in low LD, as desired.
Figure 7: Test working as desired since power is con-
stant across LD block sizes for fixed e↵ect size.
4 Eigen decomposition-based test
4.1 Description
The above approach controls for the LD structure of the region under study by transforming the test statistic
so that LD no longer a↵ects the power to detect significant regions. However, there are other ways one can
make use of the LD structure to construct more powerful tests, such as by dimension reduction. Consider
an extreme example where an investigator is interested in a region with d SNPs, and these SNPs are in
nearly perfect LD so that a correlation matrix of them has o↵-diagonal entries close to 1. Because they are
highly correlated, the association between any SNP and the outcome adds little information on top of that
between any other SNP and the outcome. As a result, intuition may tell us that using a d-d.f. test on the
region after having properly accounted for the underlying LD structure is not the most powerful approach
since there is essentially the information of 1 SNP contained in the entire region. On the other hand, it is
di cult to justify focusing on any one SNP over another as one might do when “tagging” the region. Also,
while no additional SNP contributes much information over another, there is still some amount of additional
information contained in each one that, ideally, would not be ignored.
Finding the eigenvectors and values of the information matrix is one way to approach this scenario. It
gleans the essential information from the LD block, thus stripping away extraneous information that dilutes
the power of proposed tests while avoiding the arbitrariness of pruning the number of SNPs being examined.
It is an approach similar to finding the principal components of the data matrix and then regressing the
outcome on those components if the information matrix is evaluated under the null [3, 14] and may even be
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thought of as a score test analogue to it. If certain covariates have been shown to control for population
stratification, it also may be fitting for the matrix to be evaluated under the alternative using the estimated
e↵ect sizes of those covariates. Also, as simulations demonstrate, there may be power gains under certain
correlation structures or when e↵ect or sample sizes are small. Since the information matrix is the covariation
of the scores associated with each marker and since score functions of highly correlated markers are correlated
as well, identifying the chief axes of the covarying scores is synonymous with finding the eigenvectors of the
information matrix. One can then detect small deviations from the mean under the null hypothesis, the 0
vector, by performing a parsimonious test. Additionally, if we are considering the underlying model to be that
of logistic regression, both the information matrix and the score have simple forms and are computationally
tractable.
We now describe how to construct the test, which will place no constraint on estimation of the intercept,
but reduce the dimension of the covariates underlying the scores. The score function associated with the jth
marker under a logistic regression model is
S( j) =
@L( )
@ j
=
X
i
yixij  
X
i
nixij
exp(
P
k  kxik)
1 + exp(
P
k  kxik)
.
While the (j, l)th entry in the information matrix is
Iq+1 (j,l) = Cov(S( j), S( l)) = Cov(
X
i
yixij ,
X
i
yixil)
=
X
i
xijxilP (yi = 1){1  P (yi = 1)} =
X
i
xijxil
exp(
Pk
m=0  mxim)
{1 + exp(Pkm=0  mxim)}2 ,
where we could estimate P (yi = 1) under an intercept-only model, i.e., the proportion of cases, or another
model that included potential confounders. For the sake of explanation, we will proceed as if using the
intercept-only model. The information matrix for the logistic regression model is then
Iq+1 =
266666664
Iq+1 (1,1) Iq+1 (1,2) . . . Iq+1 (1,q+1)
Iq+1 (2,1) Iq+1 (2,2) . . . Iq+1 (1,q+1)
...
...
. . .
...
Iq+1 (q+1,1) Iq+1 (q+1,2) . . . Iq+1 (q+1,q+1)
377777775 ,
where, as is consistent from our definition of Ij,l, Il,j = Ij,l. Also, I is (q + 1)⇥ (q + 1) because there are q
markers and 1 intercept available for use in the model.
Now define Iq to be the q ⇥ q information matrix for the covariates, not including the intercept. That
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is, Iq is Iq+1 without the first column and first row of Iq+1. Iq can be decomposed into EWE 1, where
E ⌘ (e1, e2, · · · , eq) is a matrix of the q eigenvectors ei, 1  i  q, and W ⌘ diag( 1,  2 · · · , q) is a
diagonal matrix of the corresponding eigenvalues  i, 1  i  q. While one can use a variable number of
eigenvectors in the analysis, if we suppose that we are in the situation described above where all dmarkers are
highly correlated, then making use of just the first component may be su cient to adequately encompass the
information contained in the genomic region. More generally, a systematic criterion for deciding which eigen
vectors to use is employing all those whose associated eigenvalues are larger than the average eigenvalue.
For the sake of explanation, we suppose first that we will construct the test using only the eigenvector
associated withe largest eigenvalue and then generalize later. Denote e1 the first column of E and vector
associated with the largest eigenvalue (assume the columns of E are ordered according to decreasing eigen-
value). The interpretation of e1 is the axis of maximum variation of the distribution whose covariance matrix
is Iq, and  1, the associated eigenvalue, can be interpreted as the variation along that axis. Since Iq is q⇥ q,
e1 is a (q⇥ 1) unit eigen vector. Define a new 2⇥ 2 information matrix I⇤ as I⇤(1,1) ⌘ Iq+1 (1,1), I⇤(2,2) ⌘  1,
and I⇤2,1 = I⇤1,2 = e1T · Iq (,1), where Iq (,1) is the first column of Iq, vT denotes the transpose of vector v,
and e1T · Iq (,1) denotes the dot product of vectors e1 and Iq (,1). The test statistic for the 1 d.f. score test
analogue of the method described in [3, 14] is then (St · e1)2 · [(I⇤ 1)(2,2)], where S is the q dimensional
vector of scores associated with the q markers, which follows a  21 distribution under the null hypothesis of
no gene-outcome association.
To generalize the method to using p eigenvectors, similar to regressing the outcome on the first p principal
components of the data matrix, again perform an eigendecomposition of Iq, and define e1, . . . , ep as the p
unit eigenvectors of length q associated with the p largest eigenvalues. Call those associated eigenvalues
 1, . . . , p. Define a new information matrix I⇤⇤ as I⇤⇤(1,1) = Iq+1 (1,1), I⇤⇤(m,m) =  m (where 2  m  p),
I⇤⇤(m,n) = I⇤⇤(n,m) = 0 (where m 6= n and 2  m,n  p), and I⇤⇤(m,1) = I⇤⇤(1,m) = emT · Iq (,1) (where
1 < m  p and Iq (,1) denotes the first column of Iq). Note that the o↵-diagonals of I⇤⇤ which are neither
the first row nor first column are zero by the orthogonality of eigenvectors; i.e., for 1 < m,n  p, m 6= n,
I⇤⇤(m,n) = I⇤⇤(n,m) = eTn · Iq · em = eTm · Iq · en = 0. I⇤⇤ is (p+ 1)⇥ (p+ 1) and looks as follows
I⇤⇤ =
2666666666664
Iq+1 (1,1) e1
T · Iq (,1) e2T · Iq (,1) . . . epT · Iq (,1)
e1T · Iq (,1)  1 0 . . . 0
e2T · Iq (,1) 0  2 . . . 0
...
...
...
. . .
...
epT · Iq (,1) 0 0 . . .  p
3777777777775
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Define I⇤⇤ 1p⇥p as the lower-right p ⇥ p sub-matrix of I⇤⇤ 1. The test statistic is ST · (e1 . . . ep) · I⇤⇤ 1p⇥p ·
(e1 . . . ep)T · S, which follows a  2p distribution under the null hypothesis of no gene-outcome association,
where again S is a vector of scores of length q.
Oftentimes in GWAS, population stratification can obscure the relationship between markers (or groups
of markers) and outcomes. In these settings, it is necessary to account for stratification by fitting models
with covariates or ancestry informative markers (AIM) that adjust for the di↵erent populations composing
the sample. Reducing the dimension of such covariates along with the markers making up the gene renders
them less e↵ective if not useless for their intended purpose of controlling for population stratification. Thus,
it is necessary to construct a score test where only a chosen subset of the covariates have their dimension
reduced and the information matrix is evaluated under the alternative for those covariates whose dimension
is not reduced. Doing so is not di cult and only requires treatment of the adjusting covariate in the quasi-
information matrix as we treated the intercept in I⇤⇤, where the o↵-diagonal entries were a linear combination
of the appropriate eigen vector and q length sub-column of the original information matrix. So suppose
there are q markers and we only want to reduce the dimension of the last (q 1) of this group. Let I(q+1) be
the (q+1)⇥(q+1) information matrix and define I(q 1) as the lower right (q 1)⇥(q 1) sub-matrix of I(q+1).
Decompose I(q 1) into E0W0E0 1, where E0 is the matrix of (q   1) eigenvectors, e0j for 1  j  (q   1), of
I(q 1) and W0 is the diagonal matrix of corresponding eigenvalues,  0j for 1  j  (q   1), and we use E0
and W0 to di↵erentiate these matrices from those defined above and not to indicate the transpose of these
matrices. Suppose we want to use the first p0 eigenvectors for our test of the (q   1) markers in the group
whose dimension we reduce and where p0  (q   1). The quasi-information matrix is defined
I⇤⇤⇤ =
2666666666664
Iq+1 (1,1) Iq+1 (1,2) e
0
1
T · Iq 1 (,1) . . . e0p0T · Iq 1 (,1)
Iq+1 (2,1) Iq+1 (2,2) e
0
1
T · Iq 1 (,2) . . . e0p0T · Iq 1 (,2)
e01
T · Iq 1 (,1) e01T · Iq 1 (,2)  01 . . . 0
...
...
...
. . .
...
e0p0
T · Iq 1 (,1) e0p0T · Iq 1 (,2) 0 . . .  0p0
3777777777775
.
Analogous to the test statistic defined in the previous test, define I⇤⇤⇤ 1p0⇥p0 as the lower-right (p
0 ⇥ p0)
sub-matrix of I⇤⇤⇤ 1 and S0 as the vector of scores associated with the (q   1) markers whose dimension we
reduce. The test statistic is S0T · (e01 . . . e0p0) · I⇤⇤⇤ 1p0⇥p0 · (e01 . . . e0p0)T · S0, which follows a  2p0 distribution
under the null hypothesis of no gene-outcome association.
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5 Simulation results
5.1 Summary statistic based test and comparison with Hotelling’s T 2
Moskvina et al. propose a test based on Hotelling’s T 2. If one knows the true information matrix, it is a
multivariate score test and follows a X2 distribution under the null. Supposing that there are q markers
and S = (S( 1), . . . , S( q))T , the associated scores, and the true information matrix is I, then under the
null of no marker being associated with the outcome, ST I 1S ⇠ X2q . Similarly, and as described above, the
summary statistic based test uses the Z-statistics associated with univariate logistic regression models, Z,
and the marker correlation matrix, V, so that under the null hypothesis and assuming V is perfectly known,
T ⌘ ZTV  1Z ⇠ X2q . While both of these approaches use similar information (i.e., some measure of SNP
significance not controlling for other SNPs and an estimate relating to the correlation of those measures), in
simulation the summary statistic based approach seems to have slightly less power than the Hotelling’s T 2
test, but the di↵erence is almost non-existent in many cases (Figures 4 and 5), and the summary statistic
based test also seems to be more conservative, again assuming a perfectly known correlation structure V .
More importantly, however, the summary statistic approach does not require individual-level data, which
is not the case with Hotelling’s T 2. Power for the summary statistic based approach does not vary as a
function of whether the causal SNP in the gene is in a region of LD or not (Figure 6), and, for a constant
e↵ect size, power does not vary as a function of the size of the LD block in the gene (Figure 7).
Simulations were generated under the same framework as we used with the permutation test simulation
above. Covariates were generated with a minor allele frequency of approximately 0.3, and, within any LD
block, correlation between SNPs was again approximately 0.65, whereas SNPs not in the LD block were
independent of one another. We assumed Hardy-Weinberg equilibrium. The gene consisted of 20 SNPs, and
there were 600 subjects with an equal number of cases and controls. Power calculations were based on 1000
iterations at each e↵ect size (e.g., Figure 4) or LD block size (e.g., Figure 5). Lastly, binary outcomes were
generated assuming a logistic regression model.
5.2 Eigen decomposition-based test
We examine in simulation performance of the dimension-reduced score test when a single causal SNP was in
an LD block and compare this proposed test with the method described in [3, 14], in addition to 1 d.f. score
and Wald tests of the causal SNP and a 1 d.f. Wald test of a tagging SNP when the correlation between
tagging and causal SNPs was approximately 0.8. Figure 8 shows relative performance of these methods when
there was no LD, while Figure 9 compares methods when correlation was approximately 0.15. We see that
the performance of the Eigen decomposition-based test performed better relative to the method proposed
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in [3, 14] when the LD block was more weakly correlated. As the correlation increases, power of these two
methods converges. Direct testing of the causal SNP, be it through a Wald or score test, performed best as
expected, though of course knowledge of the true causal SNP is generally never known. Thus, we note that
the eigen decomposition-based test performs better than testing of a tagging SNP and makes unnecessary the
need to decide which tagging SNP to use. In Figure 9, even under weak LD, the eigen decomposition-based
test pays little price in terms of power for no knowledge of the true causal SNP.
Figure 8: Power comparison between the Eigen-based
test and Gauderman’s method, along with a direct test
of the causal SNPs and tagging SNP under no LD.
Figure 9: Power comparison between the Eigen-based
test and Gauderman’s method, along with a direct test
of the causal SNPs and tagging SNP under high LD.
6 Data analysis
We analyze a sequence data set composed of 192 cases of cleft lip and 192 controls, on whom we have data
for 14 SNPs. The data come from a GWAS in which a candidate gene was identified and then sequenced
[9]. We prune the data set so that any observations with missing values or deletions are excluded, giving
172 cases and 176 controls. We also prune SNPs so that any SNP with a MAF less than 0.02 among either
cases or controls is excluded, leaving 8 SNPs. We calculate the correlation matrix of SNPs by pooling cases
and controls. Using the summary statistic based test, we find that the region composed of the 8 SNPs
is associated with cleft lip (p=0.06). Using the eigen decomposition based test with the two eigenvectors
whose associated eigenvalue is bigger than the average eigenvalue, we calculate a p-value of 0.017; using
3 eigenvectors such that more than 80% of the variation in scores is explained, we calculate a p-value of
0.016. Thus, as is consistent with the potential power gains posed by dimension reduction, this latter test
shows a stronger association between the region of 8 SNPs and cleft lip. For comparison, we also calculated
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a permutation test p-value, giving 0.008 (5000 permutations), and a Hotelling’s T 2 p-value, giving 0.056
(non-parametric, permutation-based p-value for this test gives 0.057). Assuming little correlation among
SNPs, one would expect the permutation test p-value to give a p-value similar to that of the summary
statistic based test. The greater significance of the permutation test p-value suggests that a significant SNP
is in LD with other SNPs and examination of the data matrix confirms this idea; a SNP whose p-value is
0.018 using a univariate logistic regression model is highly correlated with one SNP (r=0.71) and moderately
correlated with another SNP (r=0.43). Since only 8 SNPs are being analyzed, these two SNPs in LD with
the significant SNP may be driving the significance of the permutation test.
We also apply the summary-statistic based test to results borrowed from an already-published GWAS
along with information on the correlation of markers taken from HapMap [2, 11]. Pillai et al. (2009) identified
5 SNPs in the CDKAL1 gene on Chromosome 6 to be associated with Chronic Obstructive Pulmonary
Disorder (COPD). We run our summary statistic based test on their results. Since the results come from
a study of Norwegians, we use the (CEU) reference panel from HapMap as an estimate of the correlation
structure of SNPs. The underlying population is unlikely to be identical, however, and so we adjust the
correlation matrix, shrinking the o↵-diagonal elements toward 0 as described in the modification of the
summary statistic based test to preserve the type 1 error rate. We do so with   values of 1 (i.e., assuming
the correlation structure is correct), 0.9, and 0.8, and corresponding p-values for the 5 d.f. test are 0.0066,
0.003, and 0.001. While the summary statistics we use are borrowed from the 100 most significant SNPs
of their analysis [11], the high level of significance for tests corresponding to all   values and non-arbitrary
choice all SNPs in the chosen gene suggest that there is likely some association between the CDKAL1 gene
and COPD. Since the test statistics are themselves random variables, specific realizations of them are not
necessarily associated with increasing p-values as one would anticipate with decreases in  . However, work
above has shown that, in general, modest decreases in   should help preserve type 1 error.
7 Discussion
With the availability of sequence data and GWAS, the importance of statistical analysis is shifting from
single-locus tests to multi-loci tests that can cover genomic regions, e.g., genes or even pathways. The
motivation for this development is to test a hypothesis more grounded in biology and, at the same time, to
reduce the multiple testing problem and allow for many SNPs with a small e↵ect size to increase the power
of the test by their combined inclusion in the model. One of the theoretical issues that has so far not been
addressed adequately is the impact of LD on the power of the test statistic in permutation-based gene tests.
Controlling for the LD between loci is important to assess the relative importance of the di↵erent regions
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that are tested, especially when LD heterogeneity between regions is significant. In this paper, we have
proposed 2 approaches that address this issue.
While our summary statistic based test may give one similar results to a Hotelling’s T 2 based test, the
summary statistic test does not require the original marker data from which Z-statistics are calculated. This
unique advantage opens up the possibility for more in-depth analysis of previously published studies, and,
with su cient methodological development, could even suggest summary statistic based pathway analyses
when combined with summary statistics from expression analyses. It also opens up the possibility of cross-
study gene-based tests, where Z-statistics from the same markers are combined across previously published
GWAS to reap power gains. A shortcoming of our summary statistic based test is that if the estimated
correlation structure used in the test is not reflective of the underlying population, the test may su↵er
from inflated type 1 error. We therefore proposed an modification of the test by adjusting the estimated
correlation matrix, which, in general, should help control the error rate. If there is insu cient justification
for why the estimated correlation matrix is representative of the underlying population, the test should not
be used even with correlation matrix adjustment.
Both of the proposed gene-based tests in this paper fail to describe the direction of association between
the gene and outcome, instead describing only significance of association. Direction of association is a di cult
concept to interpret when a gene is composed of multiple SNPs, with some alleles protective and others a
risk factor for the outcome. One goal in gene-based testing might be to gain an understanding of such a
concept. Additionally and with regard to dimension reduction approaches, if alleles in a dimension-reduced
block of SNPs are both protective and harmful, there could be a loss of power using a dimension-reduction
gene-based test. A test that used a priori analyses to decide whether alleles are protective or harmful and,
in turn, used that information to inform the dimension reduction process might be another valuable area of
research in gene-based testing.
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Testing for odds ratio bias in case-control studies
David M. Swanson and Rebecca Betensky
Abstract
Survival bias is a long-recognized problem in case-control studies, and many varieties of bias can come under
this umbrella term. We focus on one of them, termed Neyman’s bias or “prevalence-incidence bias.” It occurs in
case-control studies when exposure affects both disease and disease-induced mortality, and we give a formula for
the observed, biased odds ratio under such conditions. We compare our result with previous investigations into this
phenomenon and consider models under which this bias may or may not be significant. Finally, we propose three
hypothesis tests to identify when Neyman’s bias may be present in case-control studies. We apply these tests to two
data sets, one of stroke mortality and another of brain cancer, and find some evidence of Neyman’s bias in both cases.
1 Introduction
Survival bias is a frequent source of concern in case-control studies [16, 15]. Sackett describes nine types of bias
common in case-control studies, and we focus our investigation on one of them, first identified by Jerzy Neyman
and now known as Neyman’s bias or “prevalence-incidence bias” [13]. It is a bias that occurs when exposure affects
disease and disease-associated mortality and prevalent cases are sampled. Since Neyman’s article was written in the
1950’s when the relationship between smoking and lung cancer was under debate, he uses an example that focuses on
that subject. He disregards competing risks and supposes that if, in fact, smoking is protective against lung cancer, but
lung cancer mortality is far higher among non-smokers than smokers, then the odds ratio would suggest that smoking
is a risk factor for disease as was being observed at the time.
Despite Neyman’s early identification of this bias, methodological investigation into it has been limited. Hill
(2003) uses a compartment model to show how bias arises when performing case-control studies on prevalent cases if
the risk factor impacts both disease and mortality from disease. He also shows that any impact of the risk factor on
mortality from other causes does not impact the observed odds ratio, which demonstrates that Neyman was justified in
ignoring competing risks.
Anderson et al. (2011) performed a computational investigation into Neyman’s bias, recognizing that genome-
wide association studies (GWAS) and their use of prevalent cases in case-control study designs were susceptible to it.
If an allele was a risk factor for both disease and mortality from disease, then the common practice of calculating an
odds ratio from prevalent cases and controls could lead to biased inference. Since the odds ratios in such studies are
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usually small, differences in disease-associated mortality between the exposed and unexposed would not be required
for a risk allele to be observed as protective, or vice versa. Their own investigation was motivated by a locus found
to be significantly associated with ischemic stroke in longitudinal studies that did not replicate using a case-control
design. As a solution, they simulated data under different disease and mortality risk models and then fit regression
models for % bias of the odds ratio to the disease and mortality risk model parameters. These fitted models gave
researchers a means to investigate the potential biases of estimated odds ratios in their own studies.
In an editorial response to Andersen et al.’s work, [7] noted that the bias under investigation is more than anything
an issue of study design. True case-control studies should be ones focused on incident, not prevalent, cases, and when
lacking knowledge of the time of disease onset, one can never assume that a measure of association is unbiased. So
while the work of [1] is valid, emphasis should be placed on conducting a well-executed case-control study in the
first place, not attempting to assess and correct bias of a poorly conducted one. In this paper, we examine the issue
of Neyman’s bias from a modeling perspective and suggest methods to assess whether Neyman’s bias is present in a
study.
2 Methods
2.1 Background
Assume that we have a setting similar to that described in [1], where we have some binary risk SNP or gene, G, that
takes on the value 1 with probability p (“exposed”) and 0 with probability 1  p (“unexposed”).
Suppose G has some unspecified association with Ma,i, i = 1, . . . , n, denoting age at mortality from all other
causes not associated with disease. That is, by definition of Ma,i, i = 1, . . . , n, Ma,i ?? (X D)T | G, where
W ?? Y | Z denotes statistical independence of W and Y conditional on Z, D is age at disease-onset, and X
is time from disease to the first disease-associated mortality cause. We describe X in greater detail later. Define
Ma ⌘ min{Ma,i} so that we haveMa ?? (X D)T | G.
Additionally, suppose that G may be associated with D, again age at disease, and Md,i ⌘ D + Xi, where Xi,
i = 1, . . . ,m, is time to the ith mortality cause from disease onset and may or may not be associated with D
So we have that Md,i is age at the ith disease-associated mortality and, depending on the joint distribution
(D Xi)T , Md,i may or may not be associated with D. If Xi ?? D, then Md,i is necessarily associated with D
because Md,i ⌘ D + Xi. In fact, we need Xi associated with D in a specific way to have Md,i ?? D. We do not
assume Xi is a positive random variable so that we can have P (Md,i < D)   0. While it may seem counterintuitive
to allow for disease-associated mortality prior to disease, this flexibility fits into a realistic framework. For example, if
the disease of interest is stroke, and there exists an association between death from myocardial infarction and stroke,
then indeed mortality associated with disease, though not directly caused by it, can occur before disease and can bias
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the odds ratio as is shown later. Now let us define X ⌘ min{Xi}, and similarly,Md ⌘ D +X = D +min{Xi}.
2.2 Formulae
Suppose we perform a case-control study of prevalent cases at age t⇤, and define Ca ⌘ I(t⇤  Ma), Cd ⌘ I(t⇤ 
Md), and C ⌘ min{Cd, Ca}, I(·) the indicator function, so that a subject can be thought of as observed if C = 1; i.e.,
the subject’s event time occurs before censoring by both all-cause mortality and disease-associated mortality. Denote
the cumulative distribution function associated with random variable X as FX(t). Then the target odds ratio among
the population at age t⇤ is
ORtr(t
⇤) =
pr(Case, Exposed) pr(Control, Unexposed)
pr(Control, Exposed) pr(Case, Unexposed)
=
pr(D  t⇤, G = 1)pr(D > t⇤, G = 0)
pr(D > t⇤, G = 1)pr(D  t⇤, G = 0)
=
FD|G=1(t⇤) p {1  FD|G=0(t⇤)} (1  p)
{1  FD|G=1(t⇤)} pFD|G=0(t⇤) (1  p)
=
FD|G=1(t⇤) {1  FD|G=0(t⇤)}
{1  FD|G=1(t⇤)}FD|G=0(t⇤) .
Whereas, putting no constraints on the joint model (X D G)T , the observed odds ratio among prevalent cases at
age t⇤ is
ORob(t
⇤) =
pr(Case, Exposed, Observed) pr(Control, Unexposed, Observed)
pr(Control, Exposed, Observed) pr(Case, Unexposed, Observed)
=
pr(D  t⇤, G = 1, C = 1) pr(D > t⇤, G = 0, C = 1)
pr(D > t⇤, G = 1, C = 1) pr(D  t⇤, G = 0, C = 1)
=
pr(D  t⇤, G = 1, Ca = 1, Cd = 1) pr(D > t⇤, G = 0, Ca = 1, Cd = 1)
pr(D > t⇤, G = 1, Ca = 1, Cd = 1) pr(D  t⇤, G = 0, Ca = 1, Cd = 1) .
Consider the term pr(D  t⇤, G = 1, Ca = 1, Cd = 1).
We can factor the probability as
pr(D  t⇤, G = 1, Ca = 1, Cd = 1)
=pr(D  t⇤, Cd = 1|Ca = 1, G = 1) pr(Ca = 1|G = 1) pr(G = 1).
SinceMa ?? (X D)T | G andMd ⌘ X +D, Ma ?? Md | G, and since Ca and Cd are functions of onlyMa and
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Md (with fixed and known t⇤), respectively, (D Cd) ?? Ca | G. Using this conditional independence, we have
pr(D  t⇤, Cd = 1|Ca = 1, G = 1) pr(Ca = 1|G = 1) pr(G = 1)
=pr(D  t⇤, Cd = 1|G = 1) pr(Ca = 1|G = 1) pr(G = 1)
=
Z t⇤
0
{1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t) {1  FMa|G=1(t⇤)} p.
Reducing the other terms of ORob(t⇤) in the corresponding way, we have
=
R t⇤
0 {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t) {1  FMa|G=1(t⇤)} pR1
t⇤ {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t) {1  FMa|G=1(t⇤)} pR1
t⇤ {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t) {1  FMa|G=0(t⇤)} (1  p)R t⇤
0 {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t) {1  FMa|G=0(t⇤)} (1  p)
=
hR t⇤
0 {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t)
i hR1
t⇤ {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t)
i
hR1
t⇤ {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t)
i hR t⇤
0 {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t)
i . (1)
Consider X ?? D | G, the case when time from disease to the first disease-associated mortality, X , is independent
of age at disease, D, conditional on exposure, G. The assumption may be reasonable for some exposures that are risk
factors for diseases whose course is independent of the age of onset given G. In this case, we observe
ORob(t
⇤) =
pr(Case, Exposed, Observed) pr(Control, Unexposed, Observed)
pr(Control, Exposed, Observed) pr(Case, Unexposed, Observed)
=
hR t⇤
0 {1  FX|G=1(t⇤   t)}@FD|G=1(t)
i hR1
t⇤ {1  FX|G=0(t⇤   t)}@FD|G=0(t)
i
hR1
t⇤ {1  FX|G=1(t⇤   t)}@FD|G=1(t)
i hR t⇤
0 {1  FX|G=0(t⇤   t)}@FD|G=0(t)
i .
Return to (1), and let us consider ways in which ORob(t⇤) = ORtr(t⇤) holds. Recall that Md ⌘ D + X , where X
need not be a positive random variable. Suppose that X ⌘ A D, for some positive random variable A independent
ofD, conditional on G. ThenMd ⌘ D +X = D + (A D) = A. SoMd = A and is independent ofD given G, or
in notation, Md ?? D | G. Notice that whenMd is defined in this way, an association necessarily exists between X
and D, conditional on G, since X is itself a function of D. IfMd ?? D | G holds, then (1) reduces to
ORob(t
⇤) =
h
{1  FMd|G=1(t⇤)}
R t⇤
0 @FD|G=1(t)
i h
{1  FMd|G=0(t⇤)}
R1
t⇤ @FD|G=0(t)
i
h
{1  FMd|G=1(t⇤)}
R1
t⇤ @FD|G=1(t)
i h
{1  FMd|G=0(t⇤)}
R t⇤
0 @FD|G=0(t)
i (2)
=
FD|G=1(t⇤) 1  FD|G=0(t⇤)
1  FD|G=1(t⇤)FD|G=0(t⇤) = ORtr(t
⇤),
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where (2) usesFX|D=t,G=g(t⇤ t) = FX+t|D=t,G=g(t⇤) = FX+D|D=t,G=g(t⇤) = FMd|D=t,G=g(t⇤) = FMd|G=g(t⇤).
So whenMd ?? D | G,Md functions asMa in the sense that ORob(t⇤) is no longer a function of the distribution of
Md and ORtr(t⇤) = ORob(t⇤). While Md ?? D | G is a sufficient condition for ORtr(t⇤) = ORob(t⇤), it is not
necessary; there exist multivariate distributions (X D G)T such that ORtr(t⇤) = ORob(t⇤), butMd ?? D | G does
not hold. In the hypothesis testing section of this paper, proposed tests attempt to detect deviations fromMd ?? D | G.
3 Observations
We make a few observations based on the observed and target odds ratios. We distinguish between what we will term
the “scientific null hypothesis,” that at some time t⇤, ORtr(t⇤) = 1, and the “bias null hypothesis,” that at some time
t⇤, ORtr(t⇤) = ORob(t⇤). The alternative hypothesis in both cases is the complement of the null hypothesis. The
observations are categorized in terms of whether the scientific null or alternative hypothesis is assumed.
First, under both the scientific null (i.e., ORtr(t⇤) = 1) and scientific alternative hypothesis (i.e., ORtr(t⇤) 6= 1),
even if mortality from other causes,Ma, depends on G, it does not affect the bias of the observed odds ratio; in other
words, ORob(t⇤) and ORtr(t⇤) are not a function of the distribution ofMa. Thus, we may assume, as Neyman does
in his original example and Hill (2003) confirms, that mortality from other causes is not present and death can only
occur from disease. Similarly, we see that p, probability of exposure, does not affectORob(t⇤). Also, and as expected,
if FX|G=g(t⇤) = 0 for g 2 {0, 1} (which is the case when no disease-associated mortality occurs prior to t⇤), then
ORob(t⇤) is unbiased: ORob(t⇤) = ORtr(t⇤). This result is expected since it is disease-related mortality that results
in the bias-inducing differential selection between the exposed and unexposed.
Secondly, and under only the scientific alternative hypothesis (i.e., ORtr(t⇤) 6= 1), if we suppose the following
conditions 1  4, then bias exists (i.e., ORob(t⇤) 6= ORtr(t⇤)):
1. FX|D,G=0(t⇤   t) = FX|G=0(t⇤   t) = FX|G=1(t⇤   t) = FX|D,G=1(t⇤   t) for all t (i.e., the mortality
distribution from disease-onset is identical between the exposed and unexposed and not dependent on age at
disease-onset).
2. FX|G=g(t⇤⇤) > 0 for some g 2 {0, 1} (i.e., either the exposed or unexposed have positive probability of dying
from disease by t⇤⇤, where t⇤⇤ is defined as the time between t⇤ and the first possible presence of disease among
the exposed or unexposed so that the bias-inducing event will have some chance of occurring prior to study at
t⇤).
3. pr(X > 0) = 1, implying pr(D < Md) = 1.
4. FD|G=0(x) = FD|G=1(x   k) for all x for some k 6= 0, and FD|G=0(t⇤) > 0 or FD|G=1(t⇤) > 0 (i.e.,
the disease distributions for the exposed and unexposed are in the same location family, and k 6= 0 implies
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ORtr(t⇤) 6= 1).
These assumptions seem plausible if some exposure translates the mean age of disease, though the shape of the
disease distribution is approximately the same between exposed and unexposed, and after disease occurrence, hazard
of mortality is identical among those with and without the exposure and not a function of age at disease onset. The
theorem and proof of this result is found in the Proof and examples section (Theorem 1). Additionally, in that proof
we find that when ORtr(t⇤) < 1, then ORob(t⇤) > ORtr(t⇤), and when ORtr(t⇤) > 1, then ORob(t⇤) < ORtr(t⇤).
Thus, if the degree of bias is relatively small, then it can be viewed as a bias toward an observed odds ratio of 1.
However, ORob(t⇤) is by no means bounded by 1 and so if the amount of bias is great, ORob(t⇤) and ORtr(t⇤) can
lie on opposite sides of 1, leading to wrongly inferring a truly protective exposure as a risk factor for the outcome or a
true risk factor as protective against the outcome.
This result of ORob(t⇤) 6= ORtr(t⇤) will not necessarily hold if conditions 1   3 hold, but condition 4 is not
satisfied (the distributions of disease of exposed and unexposed are not in the same location family). Under such a
scenario, there may not be bias as Example 1 in the Proof and examples section illustrates. Additionally, if we only
assume that conditions 2   3 are satisfied, then there may or may not be bias. See Examples 2 and 3 in the Proof
and examples section for instances of ORob(t⇤) = ORtr(t⇤) and ORob(t⇤) 6= ORtr(t⇤), respectively, when X is
associated with G (but is independent of D given G: X ?? D | G). It follows that if there exist no conditional
independences, one can make no conclusions regarding the relationship between ORtr(t⇤) and ORob(t⇤) as there is
even greater flexibility in the joint model. Lastly, if only X ?? G | D is assumed so that X may depend on D (i.e.,
time to disease-induced mortality may depend on age at disease-onset), again ORtr(t⇤) and ORob(t⇤) may or may
not be equal. This result follows from the proof with location families and Example 1 because they are special cases
of only assuming X ?? G | D.
Third and lastly, we compare ORob(t⇤) and ORtr(t⇤) under the scientific null hypothesis, ORtr(t⇤) = 1. If
we only assume that ORtr(t⇤) = 1 with no conditions on ORtr(t) for t < t⇤, and also that X ?? D | G
and FX|G=0(t) 6= FX|G=1(t) for some t < t⇤⇤, one cannot conclude anything regarding the relationship be-
tween ORtr(t⇤) and ORob(t⇤). Consider Examples 4 and 5 in the Proof and examples section for instances of
ORob(t⇤) = ORtr(t⇤) = 1 and ORob(t⇤) 6= ORtr(t⇤) = 1, respectively. We also observe that if ORtr(t) = 1 for all
t  t⇤ and FX|D,G=0(t) = FX|D,G=1(t) for all t < t⇤⇤, ORtr(t⇤) = ORob(t⇤) = 1.
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4 The odds ratio when T ⇤ is not fixed
If the case-control study consists of people of many ages, then t⇤, previously considered fixed, can be considered
random. Let us denote this random variable T ⇤. Under these conditions, the target odds ratio becomes
ORtr(T
⇤) =
pr(Case, Exposed) pr(Control, Unexposed)
pr(Control, Exposed) pr(Case, Unexposed)
=
pr(D  T ⇤, G = 1) pr(D > T ⇤, G = 0)
pr(D > T ⇤, G = 1) pr(D  T ⇤, G = 0)
=
R
FD|G=1(u) @FT⇤(u) p {1 
R
FD|G=0(u) @FT⇤(u)} (1  p)
{1  R FD|G=1(u) @FT⇤(u)} p R FD|G=0(u) @FT⇤(u) (1  p)
=
R
FD|G=1(u) @FT⇤(u) {1 
R
FD|G=0(u) @FT⇤(u)}
{1  R FD|G=1(u) @FT⇤(u)} R FD|G=0(u) @FT⇤(u) .
Making no assumptions about the joint model (D X Ma G)T , the observed odds ratio is
ORob(T
⇤) =
pr(Case, Exposed, Observed) pr(Control, Unexposed, Observed)
pr(Control, Exposed, Observed) pr(Case, Unexposed, Observed)
=
pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma, G = 1) pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma, G = 0)
pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma, G = 1) pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma, G = 0)
=
pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 1) pr(G = 1)
pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 1) pr(G = 1)
pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 0) pr(G = 0)
pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 0) pr(G = 0)
=
pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 1) pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 0)
pr(D > T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 1) pr(D  T ⇤, T ⇤ < Md, T ⇤ < Ma|G = 0)
While pr(G = 1) = p cancels from ORob(T ⇤) as before with ORob(t⇤), we see that even if (D X) ?? Ma | G,
we cannot factor pr(T ⇤ < Ma|G = g) out of the expression. So ORob(T ⇤) becomes a function of Ma, causes of
mortality unassociated with the disease under investigation. Additionally, regardless of whether pr(T ⇤ < Ma|G = g)
factors out of the expression,D ??Md | G, which we have stated before as being sufficient forORob(t⇤) = ORtr(t⇤),
is not sufficient for ORob(T ⇤) = ORtr(T ⇤). This point is relevant as we propose hypothesis tests below.
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5 Testing
5.1 Description
We develop three methods for testing for the presence of Neyman’s bias in a study. Again, the “bias null hypothesis”
of these tests is ORtr(t⇤) = ORob(t⇤), and the alternative is ORtr(t⇤) 6= ORob(t⇤). While power may vary as a
function of ORtr(t⇤), the tests we propose are valid under all values of ORtr(t⇤). Each of these three methods makes
use of characteristics unique to the data when Neyman’s bias is absent, and each test may be more fitting to use than
the other two under certain study designs. So, for example, Tests 1 and 2 require study observations to have some
variation in age at study entry, a random variable we denote T ⇤, while Test 3 does not, though Test 3 requires external
knowledge of population prevalence of disease and exposure, while neither Test 1 nor Test 2 do so.
We have demonstrated above thatMd ?? D | G is a sufficient condition for ORtr(t⇤) = ORob(t⇤). Ideally, we
would have data on all of D, Md, and G and could test for conditional independences. However, in practice, it may
be unlikely that one would have follow-up data on controls, in which case Md would be unknown for subjects with
T ⇤ < D, and perhapsMd would be unknown for controls as well. Thus, we propose these tests with real-world data
limitations in mind.
The first two hypothesis tests we propose attempt to test whether this independence condition holds. Both of
these hypothesis tests make use of previous work coming from the truncation methodology literature for tests of
“quasi-independence,” which refers to independence of random variables in a certain “observable” region of their joint
distribution, which we explain further below [12, 2, 18].
The last hypothesis test we propose assumes pr(D < Md) = 1, which may be unreasonable in some settings,
but reasonable in others, and depends on whether causes of mortality associated with disease can come before disease
onset. The test uses the fact that using data collected under a case-control study design along with population disease
prevalence, one can estimate the population exposure proportion. If one has knowledge of the true exposure proportion,
any comparison between the true, known value and the calculated quantity can reveal bias in the odds ratio from which
it was calculated. Thus, in contrast to the first two tests which detect a sufficient, though not necessary, condition of
unbiasedness, this latter test has power above the type 1 error whenever bias is present.
5.2 Test 1: testing for “quasi-independence” under double truncation
Tests of association using U-statistics have been proposed for double truncation settings, whereby a realization of a
multivariate random variable is only observed if left and right truncating events are satisfied [2, 12]. For example, a
double truncation setting would be one whereW is only in the sample ifW satisfies L < W , the left truncating event,
andW < R, the right truncating event. Here we modify a non-parametric association test of [2], whose null hypothesis
assumes in our context mutual independence ofD, T ⇤,Md. However, in our setting, we test only for independence of
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D andMd givenG, and our observable region is whereD < T ⇤ < Md givenG; i.e., realizations of observed (because
T ⇤ < Md) cases (because D < T ⇤) of a given exposure status. This is a valid approach to testing D ?? Md | G,
which is sufficient for no Neyman’s bias, becauseD ??Md | G necessarily implies independence in the region we are
defining as observable, D < T ⇤ < Md given G. Additionally, we focus on cases under the assumption that follow-up
data on Md is more likely to be available among them. While the power of this test may suffer in comparison to one
that makes use of all observations, the approach makes fewer assumptions on data availability, and in settings where
P (D < Md) is close to 1, power will not suffer significantly.
To implement the hypothesis test, first we categorize all causes of mortality as Md since if D and Md are as-
sociated given G, and D ?? Ma | G, then categorizing Ma as Md will maintain that association and avoid the
need to censor observations. Also, if D ?? Md | G and D ?? Ma | G, categorizing Ma as Md will maintain
D ?? Md | G. This approach is also legitimate from the perspective that Md was originally defined as causes
of mortality potentially, though not necessarily, associated with disease. Now suppose that we have 1, . . . , n real-
izations of (Gi Di T ⇤i Md,i)T , and that C0ij = 1 (alternatively, C1ij = 1) if G = 0 (alternatively, G = 1) and
max{Di, Dj}  min{T ⇤i , T ⇤j },max{T ⇤i , T ⇤j }  min{Md,i,Md,j}, the comparability criterion, is satisfied, and
C0ij = 0 (alternatively, C1ij = 0) otherwise. Define n0 ⌘
Pn 1
i=1
Pn
j=(i+1) C
0
ij and n1 ⌘
Pn 1
i=1
Pn
j=(i+1) C
1
ij .
The test statistic for the unexposed (G = 0), T0, is
T0 =
1
n0
n 1X
i=1
nX
j=i+1
sgn{(Di  Dj)(Md,i  Md,j)}C0ij ,
while the test statistic for the exposed (G = 1), T1, is
T1 =
1
n1
n 1X
i=1
nX
j=i+1
sgn{(Di  Dj)(Md,i  Md,j)}C1ij .
Then T0 ⇠ N(0, v0) and T1 ⇠ N(0, v1), where
vg = E(sgn{(D1  D2)(Md,1  Md,2) (D1  D3)(Md,1  Md,3)}Cg12 Cg13 |G = g)  (⌧gD,MdµD,Md)2
with g 2 {0, 1}, and where ⌧gD,Md = E(sgn{(D1  D2)(Md,1  Md,2)} | C12 = 1, G = g) and µD,Md = pr(C12 =
1), with sgn(x) = 1 for x > 0,  1 for x < 0, and 0 for x = 0.
Since we would reject if either T0 or T1 falls in some predetermined critical region because dependence between
D and Md given either G = 0 or G = 1 may mean ORtr(t⇤) 6= ORob(t⇤), in order to achieve a size ↵ test, we can
use a p-value threshold of ↵⇤ for T0 and T1, where ↵⇤ satisfies the equation ↵ = 1   (1   ↵⇤)2. So we propose a
test that rejects for max{abs(T0/v1/20 ), abs(T1/v1/21 )} > z1 ↵⇤/2, where abs(x) denotes the absolute value of x and
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z1 ↵⇤/2 is the (z1 ↵⇤/2)th quantile of a standard normal random variable.
Also, sinceD ??Md | G is a subset of situations for which ORtr(t⇤) = ORob(t⇤), our test is likely conservative,
though not overly so assuming that the majority of situations in which ORtr(t⇤) = ORob(t⇤) holds result from
D ?? Md | G being satisfied. Power curves for Test 1 as a function of the association between D andMd are shown
in Figures 12 and 13.
It is important here to make a reference to our observations regarding ORob(T ⇤) and ORtr(T ⇤), the odds ratio
when T ⇤ is viewed as random. In Section (4) above, we saw that the distribution forMa did not factor out of the odds
ratio even when (D X) ??Ma | G, and that additionally even under the assumption ofD ??Md | G, whether or not
the previous assumption held, ORob(T ⇤) could be biased; we needed a fixed t⇤ for these conditional independencies
to result in ORtr(t⇤) = ORob(t⇤). Thus, it may seem illogical to be proposing a test that requires variation in T ⇤,
which is precisely when the odds ratio will almost certainly be biased as shown in Section (4). If we do find that
D ??Md | G, sufficient for no Neyman’s bias, we would need to then stratify our sample according to similar values
of T ⇤ such that, within each stratum, T ⇤ can be effectively considered fixed and then calculate the odds ratio for
these different strata. We could then combine these strata into a average odds ratio if desirable or just consider each
stratum-specific odds ratio separately. This observation is also true with Test 2, where if we found D ?? T ⇤ | G,
which we will see implies D ?? Md | G under certain assumptions, then we would need to stratify by T ⇤ in the data
and calculate T ⇤ = t⇤ specific odds ratios to be unbiased for ORtr(t⇤).
5.3 Test 2: testing “quasi-independence” under left truncation
We now describe a test related to Test 1, but one which does not require knowledge ofMd. Such a test might be fitting
if a data set did not have follow-up on subjects, but did record age at onset of disease for cases. Groundwork for the
test is based on causal directed acyclic graphs (DAGs), borrowed from the causal inference literature [8].
By nature of any observation being in the study, the event I(T ⇤ < Md) = 1must be satisfied and is a conditioning
event. Additionally, by definition of I(T ⇤ < Md), there exists an association between it and both T ⇤ andMd. Thus,
we see in Figures 10 and 11 arrows between these random variables, indicative of a possible association, and a square
around I(T ⇤ < Md), indicative of a conditioning event. Applying rules of d-separation, also borrowed from the causal
inference literature, and assuming 0 < P (T ⇤ < Md) < 1 so the conditioning event is non-trivial, we see that when
there exists an arrow (i.e., a possible association) betweenD andMd,D and T ⇤ are not d-separated (or are associated,
in this case), whereas when there does not exist an arrow, D and T ⇤ are d-separated (or are not associated) [8]. So
then a lack of association between D and T ⇤ given G implies D ?? Md | G according to Figures 10 and 11, which
we know by previous work implies that Neyman’s bias is not present. Similarly, an association between D and T ⇤
implies that an association exists betweenD andMd, which we have shown previously may mean that bias is present,
except in special cases.
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We could assume D and T ⇤ are known for all observations in our data set and propose performing a test of
association for these random variables under the framework described above. However, doing so is unrealistic as it
assumes follow-up data on age at disease,D, for those observed at T ⇤ as controls (i.e., those withD > T ⇤). Thus, we
assumeD and T ⇤ are only observed for cases (i.e., those realizations satisfyingD < T ⇤) and propose a test of “quasi-
independence” between D and T ⇤ given G in the region of D < T ⇤ given G. If we assume that the independence
which holds on the region D < T ⇤ also holds for the entire joint distribution of (D T ⇤)T , then since there is an
association between D and T ⇤ given G if and only if D andMd are associated given G, this test is valid.
We describe here this proposed test of quasi-independence under only left truncation, in contrast to the double trun-
cation setting described in Test 1 [17, 12]. As before, let there be n realizations of (Gi Di T ⇤i )T , and again define B0ij
(alternatively, B1ij) similarly to how we did with C0i (alternatively, C1i ), where B0ij = 1 ifG = 0 andmax{Di, Dj} 
min{T ⇤i , T ⇤j } and B0ij = 0 otherwise, and where B1ij = 1 if G = 1 and max{Di, Dj}  min{T ⇤i , T ⇤j } and B1ij = 0
otherwise. Also, definem0 ⌘
Pn 1
i=1
Pn
j=(i+1)B
0
ij andm1 ⌘
Pn 1
i=1
Pn
j=(i+1)B
1
ij .
Then the test statistic for the unexposed (G = 0),W0, is
W0 =
1
m0
n 1X
i=1
nX
j=(i+1)
sgn{(Di  Dj)(T ⇤i   T ⇤j )}B0ij ,
while the test statistic for the exposed (G = 1),W1, is
W1 =
1
m1
n 1X
i=1
nX
j=(i+1)
sgn{(Di  Dj)(T ⇤i   T ⇤j )}B1ij .
ThenW0 ⇠ N(0, u0) andW1 ⇠ N(0, u1), where
ug = E(sgn{(D1  D2)(T ⇤1   T ⇤2 ) (D1  D3)(T ⇤1   T ⇤3 )}Bg12 ·Bg13 |G = g)  (⌧gD,T⇤µD,T⇤)2
with g 2 {0, 1}, and where ⌧gD,T⇤ = E(sgn{(D1   D2)(T ⇤1   T ⇤2 )} | B12 = 1, G = g) and µD,T⇤ = pr(B12 =
1). As with Test 1, since we would reject if either W0 or W1 falls in some predetermined critical region be-
cause dependence between D and Md given either G = 0 or G = 1 may mean ORtr(t⇤) 6= ORob(t⇤), for
a size ↵ test, our p-value threshold ↵⇤ for W0 and W1 satisfies ↵ = 1   (1   ↵⇤)2. Thus, our test rejects for
max{abs(W0/u1/20 ), abs(W1/u1/21 )} > z1 ↵⇤/2. Power curves for Test 2 as a function of the association between
D and Md are shown in Figures 12 and 13. Of these two figures, Figure 12 represents a more realistic scenario in
which the study sample size is constant between the two tests, though the number of comparable pairs differs. Figure
13 is of more theoretical interest, showing the power comparison if one were to somehow be able to hold the number
of comparable pairs between the two tests constant. Generally, the number of comparable pairs for Test 1 will be a
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strict subset of the number of comparable pairs for Test 2 because the comparability criterion is more strict for Test 1.
The larger difference in power between tests observed in Figure 13 compared to Figure 12 results from Test 1 being
calculated from more comparable pairs. While Test 1 seems more powerful in simulation in both figures, Test 2 may
be a better test for the bias since it is the selecting event of T ⇤ < Md that determines if any association between
D and Md is biasing the odds ratio. Test 2 may be more indicative of that event occurring in a large proportion of
observations than Test 1.
As mentioned at the end of the description of Test 1 and for reasons given there, if this test does not reject D ??
T ⇤ | G, implying D ??Md | G, we would again need to stratify the data by T ⇤ in order for ORob(t⇤) to be unbiased
for ORtr(t⇤).
5.4 Test 3: estimating population exposure proportion
With knowledge of disease prevalence, we can construct an estimate of the exposure in the general population from
case-control study data that is unbiased in the absence of Neyman’s bias, but biased otherwise. Thus, if the exposure
proportion in the population is also known, as might be the case in GWAS where minor allele frequencies (MAFs) are
oftentimes known for SNPs in different populations, we can test for the presence of Neyman’s bias by examining their
discrepancy. We develop one possible hypothesis test below where, again, H0 is ORtr(t⇤) = ORob(t⇤), and Ha is
the complement of H0.
If we make an assumption of pr(D < Md) = 1, then in comparing ORtr(t⇤) and ORob(t⇤), we see that their
equivalence depends on
FD|G=1(t⇤) {1  FD|G=0(t⇤)}
{1  FD|G=1(t⇤)}FD|G=0(t⇤) =
hR t⇤
0 {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t)
i h
{1  FD|G=0(t⇤)}
i
h
{1  FD|G=1(t⇤)}
i hR t⇤
0 {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t)
i (3)
if and only if
FD|G=1(t⇤)
FD|G=0(t⇤)
=
R t⇤
0 {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t)R t⇤
0 {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t)
So define p2(t⇤) ⌘ pr(G = 1|D < t⇤) = pr(G = 1 | Case at t⇤). Then defining
h(t⇤) ⌘ FD|G=1(t
⇤)
FD|G=0(t⇤)
=
pr(G = 1 | Case at t⇤)
pr(G = 0 | Case at t⇤) =
pr(G = 1 | Case at t⇤)
1  pr(G = 1 | Case at t⇤) ,
we have p2(t⇤) =
h(t⇤)
1+h(t⇤) , and defining
h⇤(t⇤) ⌘
R t⇤
0 {1  FX|D=t,G=1(t⇤   t)}@FD|G=1(t)R t⇤
0 {1  FX|D=t,G=0(t⇤   t)}@FD|G=0(t)
=
pr(G = 1 | Case at t⇤,Not censored from disease by t⇤)
pr(G = 0 | Case at t⇤,Not censored from disease by t⇤) ,
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then we have pN2 (t⇤) ⌘ pr(G = 1 | Case at t⇤,Not censored from disease by t⇤) = h
⇤(t⇤)
1+h⇤(t⇤) . When equation 3 does
not hold,
pN2 (t
⇤) ⌘ h
⇤(t⇤)
1 + h⇤(t⇤)
6= h(t
⇤)
1 + h(t⇤)
⌘ p2(t⇤).
Thus, if bias is present so that ORtr(t⇤) 6= ORob(t⇤), then h(t⇤) 6= h⇤(t⇤), and it will follow that p2(t⇤) 6= pN2 (t⇤).
This idea can be leveraged in a hypothesis test if there is external knowledge of the population exposure proportion
and population prevalence of disease.
By definition of pN2 (t⇤), its estimator, bp2N (t⇤), is the observed exposure proportion among cases whereE( bp2N (t⇤)) =
pN2 (t
⇤). Let p1(t⇤) ⌘ pr(G = 1 | D > t⇤,Md > t⇤), and since pr(D < Md) = 1 by assumption, p1(t⇤) = pr(G =
1 | D > t⇤) = pr(G = 1 | Control at t⇤). Then bp1(t⇤) is the observed exposure proportion among controls, and
E(bp1(t⇤)) = p1(t⇤).
We will estimate pN (t⇤) ⌘ p1(t⇤) {1  p⇤(t⇤)}+ pN2 (t⇤) p⇤(t⇤) with bp1(t⇤) {1  p⇤(t⇤)}+ bpN2 (t⇤) p⇤(t⇤). Also,
define p⇤(t⇤) ⌘ pr(Case at t⇤) = pr(D < t⇤), which implies {1   p⇤(t⇤)} = pr(Control at t⇤) = pr(D > t⇤). So
p⇤(t⇤) is population prevalence of disease at a common age t⇤ and is considered fixed and known. Since
pr(G = 1) = pr(G = 1 | D > t⇤) pr(D > t⇤) + pr(G = 1|D < t⇤) pr(D < t⇤)
= p1(t
⇤) {1  p⇤(t⇤)}+ p2(t⇤) p⇤(t⇤),
if p2(t⇤) = pN2 (t⇤), which indicates that ORob(t⇤) = ORtr(t⇤), then pN (t⇤) = pr(G = 1). Since we consider
pr(G = 1) fixed and known, the discrepancy between bpN (t⇤) and pr(G = 1) will inform our test.
Define  (t⇤) = p2(t⇤)  pN2 (t⇤). Then
pN (t⇤) +  (t⇤) p⇤(t⇤) =p1(t⇤) {1  p⇤(t⇤)}+ pN2 (t⇤) p⇤(t⇤) +  (t⇤) p⇤(t⇤)
=p1(t
⇤) {1  p⇤(t⇤)}+ pN2 (t⇤) p⇤(t⇤) + {p2(t⇤)  pN2 (t⇤)} p⇤(t⇤)
=p1(t
⇤) {1  p⇤(t⇤)}+ p2(t⇤) p⇤(t⇤) = pr(G = 1).
So pr(G = 1) and pN (t⇤) differ by  (t⇤) p⇤(t⇤). The variance associated with our estimate of the exposure proportion
bpN (t⇤) is
v ⌘ var{bpN (t⇤)} = {p⇤(t⇤)}2pN2 (t⇤){1  pN2 (t⇤)}
n2
 
+ {1  p⇤(t⇤)}2

p1(t⇤){1  p1(t⇤)}
n1
 
,
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where n2 is the number of cases and n1 the number of controls. We can estimate v with pˆ1(t⇤) and bpN2 (t⇤) and call
the quantity vˆ. So using a large sample approximation, we can construct an ↵ level hypothesis test for the presence of
Neyman’s bias by rejecting for     pr(G = 1)  bpN (t⇤)vˆ1/2
     ⇠ |Z| > z1 ↵/2.
The power becomes     pr(G = 1)  bpN (t⇤)vˆ1/2
     > z1 ↵/2
⇡ pr(G = 1)  {bpN (t⇤) +  (t⇤)p⇤(t⇤)}
vˆ1/2
⇠ Z > {z1 ↵/2    (t⇤)p⇤(t⇤)}/vˆ1/2),
assuming one tail probability negligible. We see that power decreases as p⇤(t⇤) decreases and increases with  (t⇤),
interpreted as the “degree of Neyman’s bias.”
Power curves for Test 3 are shown in Figure 14. Consistent with our understanding of the teat, power increases at
p⇤(t⇤) increases. In Figure 14, we assume that there is no variation in t⇤ so that p⇤(t⇤) is also fixed.
Figure 10: This DAG provides the framework for
Test 2. WhenD is not associated withMd, there is no
association between D and T ⇤, despite the condition-
ing event, using rules of DAGs. This figure represents
these random variables within each stratum of G.
Figure 11: This DAG provides the framework for
Test 2. When D is associated with Md, an associ-
ation between D and T ⇤ is induced due to the condi-
tioning event using rules of DAGs. This figure repre-
sents these random variables within each stratum of
G.
6 Data analysis
6.1 Test 2 applied to a brain cancer data set
We apply Test 2 to a brain cancer data set. Seventy-five subjects with oligodendroglioma, a common variant of
malignant brain tumors, were enrolled in a study at the London Regional Cancer Centre from 1984-1999 [3, 10].
The data set consisted of patient age at diagnosis of oligodendroglioma (i.e., age at disease, D) and age at start of
chemotherapy (i.e., entry into the study, T ⇤) in addition to genetic markers and other covariates. We consider the
marker at the 1pLOH locus, thought to potentially be associated with tumor sensitivity to chemotherapy. Applying
Test 2 to the data set, first within the exposed stratum of the 1pLOH marker, we obtain a Z-statistic of 6.85, significant
33
Figure 12: Comparison of power between tests 1
(short dashes) and 2 (long dashes) as a function of
the association between D and Md, measured by
Kendall’s ⌧ , holding the sample size constant.
Figure 13: Comparison of power for tests 1 (short
dashes) and 2 (long dashes) as a function of theD and
Md as measured by Kendall’s ⌧ , holding the number
of comparable pairs constant.
at the 0.05 level (p < 0.001). The sample size was insufficient to apply the test to the unexposed stratum. However,
since a significant test statistic within any stratum is sufficient for rejection of the null hypothesis, we reject the null
hypothesis of D ?? Md | G and conclude that there could be an association between D and Md within strata of G.
The result of the test suggests that if one were to calculate an odds ratio of oligodendroglioma for the 1pLOH marker
at a fixed age of subjects, the result may be biased.
6.2 Test 3 applied to a stroke-mortality data set
We apply Test 3 to a GWAS data set of ischemic stroke coming from a cohort based at Massachusetts General Hospital.
We use a wide interval estimate of ischemic stroke prevalence, ranging from 0.5%-5%, based on a search of the stroke
literature [6, 11, 5]. With this range of p⇤(t⇤), we reconstruct what would be population exposure proportion, which is
unbiased for the true population exposure proportion assuming that Neyman’s bias is not present. We calculate a test
statistic based on the difference between the true population exposure proportion and our estimate of it, divided by an
estimate of the standard error. Using a 0.0005 Bonferroni-adjusted significance level, we find that 42 of the 99 SNPs
in the study suggest that Neyman’s bias may be present. The interpretation of this result is that, were one to calculate
an odds ratio for stroke mortality with any one of these 42 SNPs, that odds ratio may be biased.
7 Discussion
While our result for Test 2 with the brain cancer data suggests that Neyman’s bias may be present because the within
stratum association between D and T ⇤ suggests a within stratum association of D andMd, we should restate that an
34
Figure 14: Power for test 3 as a function of p⇤(t⇤) and the relative probability of observing the unexposed cases versus
exposed cases. As the relative probability increases (i.e., it is more likely to observed unexposed cases than exposed
cases) as is the case when there are a greater number of mortality-inducing events among the exposed, there is more
bias and power. The solid, dashed, and dotted lines represent population prevalences of disease (p⇤(t⇤)) of 0.1, 0.2,
and 0.3, respectively.
association within strata does not necessary imply that bias is present; it is only when the independence holds that
we can conclude that Neyman’s bias is not present. Additionally, the study design may contribute to a within strata
association between D and T ⇤ and so the authors suggest that more work is needed to form stronger conclusions
regarding the potential presence of Neyman’s bias in this study.
As with the result from Test 2, the rejection of the null hypothesis of no Neyman’s bias in the stroke-mortality data
by Test 3 needs confirmatory analyses. A primary concern is that if the population underlying the measurements in
dbSNP, the source of our “true” population MAFs against which we compare the estimate, is significantly different
than that composing the study subjects, the type 1 error could be inflated. Since for many of the SNPs in the data set,
the MAF among cases and the MAF among controls did not contain the population MAF, which should be the case as
the sample size gets large, there is some evidence of different underlying populations. Another assumption that may
not be satisfied is pr(D < Md) = 1. While pr(D < Md) = 1 is unlikely to ever be fully satisfied, ischemic stroke
is an event with numerous comorbidities and so violations of the assumption may be too large for a valid test [14, 4].
Lastly, description of Test 3 showed that the power for detection of bias goes to 0 as the population prevalence of
disease gets small. The implication of this result is that any bias detected when population prevalence of disease
ranges over a relatively small 0.5%-5% is more likely due to unsatisfied assumptions than genuine Neyman’s bias.
We did not use Test 1 on the brain cancer and stroke data sets because of an insufficient sample size and insufficient
covariates, respectively. The sample size was insufficient in the brain cancer data set because the comparability
criterion for Test 1 is more stringent than that for Test 2 and so there are only a limited number of pairs of observations
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that can contribute to estimation of the necessary parameters, especially when overlap between the multivariate random
variables (D T ⇤ Md)T is minimal. Thus, while Test 2 might be thought of as somewhat removed from testing
D ??Md | G because it testsD ?? T ⇤ | G as a proxy for it, one advantage of Test 2 over Test 1 is that there are fewer
restrictions imposed by the comparability criterion, allowing for more flexible use of the data.
8 Proof and examples
We give the proof of the direction of Neyman’s bias under certain modeling assumptions and examples of when
Neyman’s bias does or does not occur, both referenced in the Observations section of this paper.
Theorem 1. IfG is associated withD such thatOR(t⇤) 6= 1, the distribution ofD | (G = 0) andD | (G = 1) belong
to the same location family, pr(X > 0) = 1, pr(X < t⇤⇤) > 0 (where t⇤⇤ is defined as the time between t⇤ and the
first possible presence of disease among the exposed or unexposed), andX ?? (D G)T , thenORob(t⇤) 6= ORtr(t⇤).
Specifically, if D | (G = 0) is stochastically greater than D | (G = 1) (alternatively, stochastically less than)
so that exposure is a risk factor for disease (alternatively, protective against disease), then ORob(t⇤) < ORtr(t⇤)
(alternatively, ORob(t⇤) > ORtr(t⇤)).
Proof. Define @FD|G=0(x)/@x = f0(x) and @FD|G=1(x)/@x = f1(x), and suppose that f1(x) = f0(x   k) for
some k positive, without loss of generality. Such a scenario corresponds to exposure being protective against disease,
though below we will also consider it a risk factor. f1(x) and f0(x) are in the same location family. Define F (x) as
the cumulative distribution function of X evaluated at x and remember F (0) = 0 and F (t⇤) > 0. Consider the two
quantities: R t⇤
0 {1  F (t⇤   x)}f0(x)@xR t⇤
0 f0(x)@x
and
R t⇤
0 {1  F (t⇤   x)}f1(x)@xR t⇤
0 f1(x)@x
,
which we call the “percent erosion” of
R t⇤
0 f0(x)@x and
R t⇤
0 f1(x)@x, respectively. Then
R t⇤
0 {1  F (t⇤   x)}f1(x)@xR t⇤
0 f1(x)@x
=
R t⇤
0 {1  F (t⇤   x)}f0(x  k)@xR t⇤
0 f0(x  k)@x
=
R (t⇤ k)
 k
⇥
1  F{t⇤   (x+ k)}⇤f0(x)@xR (t⇤ k)
 k f0(x)@x
.
Since F (·) a cumulative distribution function and therefore increasing, we have
R t⇤
0 {1  F (t⇤   x)}f1(x)@xR t⇤
0 f1(x)@x
=
R (t⇤ k)
 k
⇥
1  F{t⇤   (x+ k)}⇤f0(x)@xR (t⇤ k)
 k f0(x)@x
>
R t⇤
0 {1  F (t⇤   x)}f0(x)@xR t⇤
0 f0(x)@x
, (4)
because at every “successive” @x in each integral, 1 F{t⇤  (x+k)}   1 F (t⇤ x) and there is some 0 < x < t⇤
for which 1 F{t⇤  (x+k)} > 1 F (t⇤ x). Thus, the “percent erosion” of f0(x) will always be greater than that
of f1(x) = f0(x   k), which is intuitive since f1(·) is located to the right of f0(·) and thus subject to the corrosive
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effects of F (·) for less “time.” Then using the inequality in (4),
1 >
R t⇤
0 (1  F (t⇤   x))f0(x)@xR t⇤
0 f0(x)@x
 
/
R t⇤
0 (1  F (t⇤   x))f1(x)@xR t⇤
0 f1(x)@x
 
=
R t⇤
0 f1(x) @x pR t⇤
0 f0(x) @x (1  p)
⇥
R t⇤
0 {1  F (t⇤   x)}f0(x) @x (1  p)R t⇤
0 {1  F (t⇤   x)}f1(x) @x p
=
pr(Case, Exposed)
pr(Case, Unexposed)
⇥ pr(Case, Unexposed, Observed)
pr(Case, Exposed, Observed)
,
which implies that
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
>
pr(Case, Exposed)
pr(Case, Unexposed)
and ORob(t⇤) > ORtr(t⇤)
since pr(X > 0) implies pr(Control, Exposed, Observed) = pr(Control, Exposed) and
pr(Control, Unexposed, Observed) = pr(Control, Unexposed). Again, these inequalities only hold when exposure is
protective against disease. When exposure is a risk factor for disease and therefore shifts the mean age of disease onset
to the left under the above assumptions,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
<
pr(Case, Exposed)
pr(Case, Unexposed)
and ORob(t⇤) < ORtr(t⇤)
using analogous results. So we see that the bias is not toward the null, but in a definite direction depending on model
assumptions.
Example 1. Consider D | (G = 1) uniform on (0, 2), D | (G = 0) uniform on (0, 1), and X uniform on (0, 3),
independent of G. Clearly the distributions of disease for exposed and unexposed are not in the same location family
in this case, and the model for X corresponds to disease-induced mortality necessarily occurring within 3 times units
after disease, D. We need only consider cases when investigating the odds ratio since we assume pr(X > 0) = 1,
implying pr(D < Md) = 1. Taking t⇤ = 1,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
=
R 1
0 (2/3 + x/3) (1/2) p @xR 1
0 (2/3 + x/3) 1 (1  p) @x
=
1/2
R 1
0 (2/3 + x/3) p @x
1
R 1
0 (2/3 + x/3) (1  p) @x
=
1 p
2 (1  p) =
pr(Case, Exposed)
pr(Case, Unexposed)
.
So we have X independent of exposure status and time of disease-onset, as was the case above, but here ORob =
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ORtr.
Example 2. Consider again D | (G = 1) uniform on (0, 2), and D | (G = 0) uniform on (0, 1). However, consider
X | (G = 1) uniform on (0, 3) andX | (G = 0) with density fX|G=0(x) = 2/3 (1 x)2 on [0, 1+ (9/2)1/3]. Again,
we need only consider cases when investigating potential bias of the odds ratio since we assume pr(D < Md) = 1 so
that controls are not subject to the bias-inducing mortality event. Taking t⇤ = 1,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
=
R 1
0 (2/3 + x/3) (1/2) p @xR 1
0 (7/9 + 2x
3/9) 1 (1  p) @x
=
1/2 · R 10 (2/3 + x/3) p @x
1
R 1
0 (7/9 + 2x
3/9) (1  p) @x
=
1/2 (5/6) p
1 (5/6) (1  p) =
1 p
2 (1  p) =
pr(Case, Exposed)
pr(Case, Unexposed)
,
and so here we have no bias again.
Example 3. Assume the same models of D conditional on G, and suppose X | (G = 1) is uniform on (0, 3) and
X | (G = 0) has density fX|G=0(x) = 5/2 (1   x)4 on [0, 1 + 21/5]. For the reasons given above, we again only
consider cases for investigating the bias of the odds ratio. Taking t⇤ = 1,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
=
R 1
0 (2/3 + x/3) (1/2) p @xR 1
0 (1/2 + x
5/2) 1 (1  p) @x
=
1/2
R 1
0 (2/3 + x/3) p @x
1
R 1
0 (1/2 + x
5/2) (1  p) @x
=
1/2 (5/6) p
1 (7/12) (1  p) 6=
1 p
2 (1  p) =
pr(Case, Exposed)
pr(Case, Unexposed)
,
and so here we have bias.
Example 4. TakeD | (G = 1)with density fD|G=1(x) = x2/4 on [0, 121/3],D | (G = 0)with density fD|G=0(x) =
x/3 [0, 61/2]. Then letX | (G = 1) have density fX|G=1(x) = (2 x)2/4 on [0, 2+41/3] andX | (G = 0) be uniform
on [0, 2]. As before, we need only consider cases when investigating the odds ratio since we assume pr(D < Md) = 1
so that controls are not subject to the bias-inducing mortality event. Taking t⇤ = 2,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
=
R 2
0 (1/3 + 1/12x
3) (x2/4) p @xR 2
0 (x/2)x/3 (1  p) @x
=
(4/9) p
4/9 (1  p) =
p
R 2
0 (x
2/4) @x
(1  p) R 20 x/3 @x =
p
1  p =
pr(Case, Exposed)
pr(Case, Unexposed)
.
Remember that pr(Case, Exposed)/pr(Case, Unexposed) = p/(1   p) implies ORtr(t⇤) = 1 when pr(D <
Md) = 1, which is assumed from condition 3.
Example 5. On the other hand, we can obtain a biased odds ratio using the same conditional disease models as in the
previous example and having X | (G = 1) with density fX|G=1(x) = (2   x)2/4 on [0, 2 + 41/3] and X | (G = 0)
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uniform on [0, 2]. We again assume pr(D < Md) = 1 from condition 3. Taking t⇤ = 2,
pr(Case, Exposed, Observed)
pr(Case, Unexposed, Observed)
=
R 2
0 (1/2 + 1/16x
3) (x2/4) p @xR 2
0 (x/2)x/3 (1  p) @x
=
p (1/2)
(1  p) 4/9
6= (4/9) p
4/9 (1  p) =
p
R 2
0 (x
2/4) @x
(1  p) R 20 x/3 @x =
p
1  p =
pr(Case, Exposed)
pr(Case, Unexposed)
.
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Research participant compensation: a matter of statistical inference as well as ethics
David M. Swanson and Rebecca Betensky
Abstract
The ethics of compensation of research subjects for participation in clinical trials has been debated for
years. One ethical issue of concern is variation among subjects in the level of compensation for identical
treatments. Surprisingly, the impact of variation on the statistical inferences made from trial results
has not been examined. We seek to identify how variation in compensation may influence any existing
dependent censoring in clinical trials, thereby also influencing inference about the survival curve, hazard
ratio, or other measures of treatment e cacy. We propose a model for how compensation structure may
influence the censoring model. Under existing dependent censoring, we estimate survival curves under
di↵erent compensation structures and observe how they a↵ect the bias of the curve. If the compensa-
tion structure a↵ects the censoring model and dependent censoring is present, then variation in that
structure a↵ects the accuracy of estimation and inference on treatment e cacy. We illustrate the asso-
ciation between compensation and censoring time under one model. However, as long as compensation
a↵ects censoring, and censoring is associated with the event time (i.e., dependent censoring), variation
in compensation will result in variation in (biased) inference. From the perspectives of both ethics and
statistical inference, standardization and transparency in the compensation of participants in clinical
trials is warranted.
1 Introduction: motivation and assumptions
In recent years, there has been increased pressure on investigators to disclose their financial stakes in clinical
trials due to concerns over conflicts of interest [9]. Despite this emphasis on transparency, there are no
requirements for disclosure regarding payments to research subjects or compensation of investigators for
accrual and retention of trial participants. We investigate how variation in these incentives could a↵ect
statistical inference through their e↵ect on the retention and drop-out (i.e., censoring) processes. While it is
possible that incentives also a↵ect the event time, this is less likely because the event time is often a function
of physiological processes. Much of our examination hinges on a background of dependent censoring, i.e., an
association between event and censoring times. This is a common feature of clinical trials and impedes valid
time-to-event analysis. No attention has been paid in the literature to how incentive structures influence
and interact with dependent censoring. However, in the case of some statistical tests, dependent censoring
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is not even required for an association between incentives and censoring to invalidate inference [1]. In
particular, variation in incentives across trials for research participants, as well as for investigators, may
contribute to corresponding variation in participant censoring both dependent and independent patterns
and, consequently, inference. In this paper, we use the terms incentive,” compensation,” and reward”
interchangeably, all in reference to the payment used to minimize participant drop-out in clinical trials. It
is also important to emphasize at the outset of this investigation that, while we posit that payment may
be the chief source of unaccounted-for variation across trials, we can consider payment more generally. For
example, it may be a psychological reward such as personal encouragement for retention and compliance from
an investigator or caregiver who may be compensated or personal satisfaction from adherence to cultural
norms that are specific to study site (this is especially true for international, multi-center trials).
Compensation for subjects varies across trials in its magnitude and in its distribution over the course of
the trial and can a↵ect the censoring model in these two ways. Suppose that subjects in a trial who have
early event times are inherently more likely to drop out of the trial before their event times are observed
than subjects with late event times, so that dependent censoring is present. If there exists an incentive
su ciently generous to convince all subjects to stay on the trial, an unbiased estimate of the survival curve
will be available simply because everyone is observed, despite the underlying propensity for worse-performing
subjects to be censored. However, if the incentive in a di↵erent trial is modest, some proportion of subjects
will be informatively censored and the resulting survival curve will be biased. Suppose that subjects in one
trial are o↵ered an incentive that is allocated early in the trial in an attempt to shorten the accrual period,
which tapers later in the trial to minimize cost, while subjects in a di↵erent trial are o↵ered an incentive
that is allocated later in the trial to maximize trial retention and completion. If near- term incentives a↵ect
subjects’ follow-up di↵erently than future incentives, heterogeneity in the censoring distributions across trials
is introduced.
In this paper, we first summarize current compensation practices. We then summarize ethical perspectives
on the compensation of research subjects. We discuss the potential impact of varying reward structures on
cross-trial comparisons and analyses. We posit one plausible censoring model that is a function of the
incentive structure and other factors, and through simulation, investigate the variation in estimation of the
survival distribution. We demonstrate that reward structures may influence estimated treatment e cacy
and so it is important to incorporate this information in statistical analyses and disclose it in the reporting
of trials. We encourage journals to add this reporting requirement along with those for conflict of interest
and registration of clinical trials.
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2 Current clinical trial compensation practices
The few papers that have been published on practices of research subject inducement and compensation
in clinical studies reveal variation and a lack of structure in the incentives subjects receive for procedures.
Grady et al. [7] surveyed practices of subject payments in 2005 and found that of the 467 surveyed studies,
78% did not specify amount of payment per procedure in the study protocol or subject consent document,
and 71% did not specify payment per hour or visit. Some procedures, such as endoscopy, showed little
variation in remuneration (consistently $100), while others had considerable variation, such as MRIs ($25-
$120) and venipuncture ($10-$50). When payment per visit was recorded, there was variation from $10 to
$250. From a broader perspective, compensation for an entire study varied from $5 to $2000, though that
variation is partly a function of the study time required and procedure invasiveness. Sixty-six of the studies
surveyed were multi-site and 85% of them showed variation in payment across sites. The range of variation
was as large as $1000, and the mean and median of inter- site variation were $228 and $120, respectively.
Dickert et al. [4] performed their own analysis of payment practices by investigating 32 research organiza-
tions, which spanned the academic, pharmaceutical, contract research organization (CRO), and independent
institutional review board (IRB) sectors. The researchers found that only 37.5% of these organizations had
specific policies in place regarding payment of research subjects, and as a result, there was no standard of
compensation. Indeed, only 18.8% of organizations could even give a confident estimate of the proportion
of their studies that were paid. There was also variation in how organizations viewed payment, be it as
an incentive to participate (58% of organizations) or compensation for time, inconvenience, or risk. Half of
the written guidelines for payment that the investigators reviewed explicitly stipulated that risk should not
be compensated. One-fourth of the organizations surveyed had formulas for payment, though the level of
specificity varied. When an hourly rate was specified, it varied from $4 to $10. Some organizations paid by
day or visit, and payment varied from $25 to $125.
3 Compensation from an ethical perspective
Compensation of research subjects in clinical trials has been an active area of discussion in the ethics
literature. Two questions posed in the literature are whether it is ethical for di↵erent research subjects to be
incentivized di↵erently for the same procedure, and what constitutes “undue” inducement to participate in
research, the latter of which is forbidden by the U.S. Common Rule for the Protection of Human Subjects.
Here we summarize thinking on both these and other topics. Informed consent is the backbone of ethical
conduct of clinical trials, and one aspect of it is the voluntary choice of research subjects to participate [6].
Two elements of voluntariness include the absence of both coercion and “undue inducement” for participation.
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Grady [6] argued that physical coercion is not an issue in trials, and current payment methods do not
constitute “undue inducement” to participate, but rather should be viewed as compensation for playing a
necessary role in a successful clinical trial. Macklin [12] noted that “due” versus “undue” inducement is a
relative concept, as what might be due inducement to a lawyer is undue inducement to a minimum wage
worker. Thus, identification of an ethical threshold of payment is di cult.
Some authors have approached the definition of undue inducement from the perspective of labor relations
and have advocated a wage-payment model of compensation [5]. The tenets of this model are justice, equity,
and caution to not make payment so appealing that it is coercive. In contrast, McNeill [13] rejected the
idea of research subject payment outright, arguing that the relationship between investigator and subject is
unlike that between worker and employer due to the unknown nature of the risks involved. As a result of
payment, subjects are unable to adequately assess risks. He argued that since investigators may value their
research interests above the well-being of subjects, it is best that subjects are left to volunteer.
While McNeill [13] saw value in individual autonomy, he argued that equitable safeguards come prior to
those rights. Even though Macklin [12] recognized the danger of paternalism, she, like McNeill, saw a role
for providing safeguards that are in the subjects own best interests. She suggested that inducements should
err on the low side and that a study may be deemed unethical if an inadequate number of research subjects
are not inclined to participate in those circumstances. To that same end, Grady [6] argued that payment
should be standardized so that it is similar to that of other unskilled labor in the surrounding community.
Lemmens and Elliot [10] argued that the nature of the ethical relationship between a research subject and
an investigating institution depends on the health of the subject. Subjects who are ill and therefore stand a
chance of receiving therapeutic benefit from experimental treatments are in a vastly di↵erent position than
healthy subjects whose primary motivation for participation is compensation. In the latter case, Lemmens
and Elliot, along with other writers, maintained that the relationship should be viewed as that of a labor
contract and have similar protections.
4 Impact of varying reward structures
If payment or some other factor altered the underlying dependent censoring mechanism, one would expect to
see variation in outcomes of the placebo arms of trials of similar patient populations if incentive variation is
present. Schneider and Sano [17] summarized cognitive decline as measured by ADAS-Cog in placebo arms
of phase II and III Alzheimers drug clinical trials. They reported that even for moderate sample sizes of
107   317, the range of the mean decline over 18 months was 4.3 to 9.1 points. Although it is not possible
to definitively identify the cause for the placebo group variation, di↵erences in participant demographics
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across Alzheimers drug trials does not seem to explain the observed variation since study subjects had
similar ages, education levels, APOE e4 genotypes, baseline ADAS-Cog scores, and there was consistency
in study eligibility criteria [17]. It would be useful to know what incentives were provided to caregivers
and site investigators associated with these trials. Interestingly, two di↵erent trials of the same drug and
similar design had mean cognitive declines closer to one another, suggesting that, be it through consistency
of payment or other factors, trials with common features may cause similar subject behavior.
When unexplained variation in the placebo arms of trials is present, it raises doubts about the valid-
ity of meta-analysis. In the case of Alzheimers disease, if the variation in placebo arm mean cognitive
decline were reflective of biased estimation, the results would not be strengthened by meta-analysis since
combining biased results does not diminish bias. With increasing pressure for open access to information
and data for public dissemination and meta-analysis, this issue should be recognized. For example, the
Alzheimers Disease Cooperative Study (ADCS) provides data from placebo arms of Alzheimers clinical tri-
als for public use (www.adcs.org), the Prize4Life foundations Amyotrophic Lateral Sclerosis (ALS) Pro-
Act database provides data from placebo arms of ALS clinical trials (www.prize4life.org), and the CDCs
Tuberculosis Trials Consortium (TBTC) gives investigators involved in the consortium access to the data
(www.cdc.gov/tb/topic/research/tbtc). If the incentive structures used in these studies impacted the reten-
tion to the studies, and if they are not known and adjusted for in the meta-analyses, any conclusions are
likely to be invalid.
5 Simulation study
We illustrate through simulation how variation in research participant compensation could lead to variation
in inference on the survival curve. We consider a particular model for censoring in order to encode the
relationship between censoring and compensation and to investigate how that relationship might further
influence the underlying dependent censoring. We estimate the survival curve using the Kaplan-Meier
estimator [8] under various compensation structures and graph the results to demonstrate
the variability of the curve (see Figure 15). We do not graph the true event survival distribution in any
of the figures in order to emphasize the variability in estimation introduced by di↵erent incentive structures
and because bias is already present when there is dependent censoring, regardless of the incentive structure.
6 Event and censoring models
We simulated clinical trials with 40, 000 subjects. Half of the subjects had covariate Zi equal to 0 and half
had Zi equal to 1. For example, Zi might be socio-economic status (SES), which a↵ects both subjects event
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times (since SES is associated with health) and censoring times (since those in higher SES strata may stay on
the trial longer or shorter, depending on the situation). In simulations used to generate Figure 15, the event
times of those with Zi = 0 were distributed as Gamma(6, 7/12) (shape parameter 4 and rate parameter 5/6),
and those with Zi = 1 were distributed as Gamma(4, 5/6). In all simulations, we rounded up the generated
event times to make them discrete. The discrete event times are interpreted as the time points at which a
subject was observed to have had an event.
A subjects event time was observed if it occurred prior to the minimum of the subjects randomly generated
censoring time and 10 time units. The model for the discrete time hazard of censoring at time j for subject
i for all simulations was
logit P (Subjecti censored at time j|Not censored prior to time j, Zi) = ↵j + µ · mj +   · Zi + ⇢ · j
where logit(p) = log(p/(1 p)), ↵j helps control the overall proportion of censoring at each time period j,   is a
constant across time periods and subjects and controls to what extent the covariate Zi influences the censoring
hazard, ⇢ controls the degree to which subjects become “tired” of being involved in the trial and want to
drop-out, µ controls the influence of the incentive mj on the hazard of censoring, and mj is a function of the
incentive structure over the remaining time periods in the trial and the “incentive anticipation” parameter (or
equivalently, decay parameter) described below. We define mj as mj =
Ptot
k=j incentivek · dec(tot k), where
tot is the total number of follow-up periods (10 in our case), incentivek is the incentive size at time period
k, and dec is the decay or compounding parameter (0.88 in our case). Dependent censoring is present in the
simulation because covariate Zi a↵ects the hazard-of-censoring (through  ) and the event time (because the
gamma distribution parameters depend on Zi), and we do not condition on the covariate when estimating
the survival curve.
The total amount of the incentive for all of the structures shown is 28 units, but those units are distributed
in three di↵erent ways for the three survival curves shown in Figure 15. Each survival curve corresponds to
a certain incentive structure, and that corresponding incentive structure is shown in Figure 16. Under all
structures, payout of the 28 units is static at a level of two in 8 of the 10 follow-up periods, but then jumps
to a higher payout of six for two consecutive follow-up periods at di↵erent times during the simulated trial.
A structure with an early jump represents a trial whose investigator wants quicker subject accrual, while
the structure with a later jump represents a trial whose investigator desires complete follow-up. Parameter
values for all simulations were ↵ = (18.5, 16.5, 14.5, 11.5, 11.5, 11.5, 8.5, 8.5, 8.5, 8.5, 8.5), µ = 1,   =  8/3,
and ⇢ = 1/60.
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7 Results
Figure 15 depicts downward biased survival curves calculated with the Kaplan-Meier estimator [8] under
the di↵erent incentive structures shown in Figure 16, where there is a color correspondence between the
estimated survival curve and the incentive structure used in the associated censoring model. Di↵erences
in the survival curves in Figure 15 illustrate that when dependent censoring is present and the incentive
structure a↵ects the censoring model, variation in incentive structure results in variation in the curve.
While the simulation is conducted under a particular censoring model, the qualitative role of the incentive
within the model is highly plausible. Indeed, an association between incentive structure and censoring time
is the only assumption needed for this discussion to be relevant; in the presence of dependent censoring,
incentives are a source of significant variation that could lead to variation in inference via the censoring
model.
Figure 15: Survival curves generated under the di↵erent
incentive structures shown in Figure 16.
Figure 16: Incentive structures corresponding to the
survival curves shown in Figure 15.
8 Adjustment for incentives
Having established the impact of heterogeneity in incentive structure across trials, or across sites within
a single trial, we turn to an examination of potential analytic adjustments that might be made. We first
note that adjustment for trial or site in an analysis would not be su cient to account for inter-trial or
inter-site variation since the issue invalidating inference is neither a main e↵ect of trial or site, nor clustering
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of observations, but rather potential violation of the event and censoring time independence assumption,
fundamental to most time-to-event analyses. Sensitivity analysis is a good way to assess how analysis
assumptions influence inference. An Institute of Medicine study [2] was commissioned to study the problem
of missing data in clinical trials, and two associated articles have highlighted the importance of sensitivity
analysis in the context of missing data, of which censored survival data is a subcategory [11, 20]. The
Institute of Medicine report [2] in particular recommended specific ways of conducting sensitivity analysis
with time-to-event data. One such way is to use auxiliary prognostic factors to explain residual dependence
between event and censoring times within strata of model covariates. If these prognostic factors are not
su cient to explain the dependence, other frameworks are suggested in which a non- identifiable censoring
bias parameter that encodes residual dependence can be manipulated to investigate sensitivity of inference to
it [16, 2]. Regardless of the context in which sensitivity analysis is performed, both the Institute of Medicine
report and corresponding New England Journal of Medicine editorial state that it is important to know how
robust analysis findings are to missing data assumptions [2, 20]. Shih [18] also recognized the importance
of sensitivity analysis in clinical trials in which dependent censoring may be present, though recommended
assessing sensitivity using a broader class of missing data approaches, such as multiple imputation and non-
parametric rank-based methods. Since it is only when the assumption of independent censoring and event
times is violated that varying payment structures may lead to variation in survival curve or hazard ratio
estimates, correcting for its possible violation is important. Correction for dependent censoring and analysis
of sensitivity to the assumption of independent censoring can be done using a weighting scheme described
in Robins (1993) and Robins and Finkelstein (2000). The weight placed on any individual at time t is the
inverse of the probability of being censored by time t. Thus, those who are more likely to be censored are
weighted more in a given model, the idea being that they are “stand-ins” for subjects similar to themselves
who were unobserved because of a high hazard of being censored. Weights are calculated by modeling the
hazard of censoring within strata of the covariates already included in the hazard or survival model of interest
using additional covariates that could possibly predict censoring. These weights can then be used in the
inverse probability weighted (IPW) analogue of the Kaplan-Meier estimator:
ST (t|z) =
Y
{i;Xi<t}
1  ⌧iWi(Xi)I(Zi = z)Pn
k=1 Yk(Xi)Wk(Xi)I(Zk = z)
where ⌧i is the event indicator for subject i, Zi is the covariate or indicator of stratum, Yi(t) is an indicator
for presence in the risk set at time t, I(·) is the indicator function, and Xi is the observed event or censoring
time. The weight,Wi(t), is set to 1 in the case of the typical Kaplan-Meier estimator, and is the inverse of the
probability of remaining uncensored up to time t for the weighted Kaplan-Meier estimator. That probability
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can be estimated in di↵erent ways, including by fitting a Cox model [3] within strata of Zi, conditional
on covariates that may influence censoring. In our case, weights were obtained by first calculating the
proportion of censored individuals within each stratum of the covariate at each time period j among the
risk set, giving the hazard of censoring, hj(Zi). With this information, probability of remaining uncensored
to time t given the covariate was calculated by taking the product of one minus the hazards up to t:
Pi(t) =
Q
{j<t}(1   hj(Zi)). Weights were calculated using Wi(t) = 1/Pi(t) so that individuals more likely
to be censored by time t were weighted more than those less likely to be censored. We see in Figure 17
that when dependent censoring is present and there are two di↵erent incentive structures, there are two
corresponding and di↵erent survival curves estimated, though the underlying event model is identical for
both curves. However, after correcting for the dependent censoring using weights, we observe in Figure 18
that there is far less variation between the two estimated survival curves because the estimator is unbiased
and therefore its expectation is una↵ected by incentives. One might propose to somehow adjust for varying
incentives themselves to reduce estimate variation, though proper adjustment would require knowledge of
the relationship between incentives, other covariates, and the censoring hazard. Apart from such knowledge,
there is no clear method for adjustment and so we focus our correction recommendation on the underlying
issue of dependent censoring. If there are multiple trials of an identical therapy in the same participant
population with dissimilar survival curves for the placebo arms, it might indicate that dependent censoring
is present and di↵erent payment structures are a↵ecting the censoring model. We therefore recommend
that one should attempt to first calculate weights for each trial by modeling the hazard of censoring using
prognostic factors likely to predict it. Then, using the procedure described in Robins and Finkelstein (2000),
one should calculate a weighted Kaplan-Meier survival curve for each trial. If the placebo arms of the
trials show less variability across trials, which should be the case if entry criteria are similar and sample
sizes are adequate, correction for dependent censoring may be su cient and treatment e cacy within each
trial can be analyzed. While there is no way to test for the presence of dependent censoring in either the
weighted or unweighted Kaplan-Meier estimator, such a procedure may give researchers additional insight
into clinical trials data and the robustness of their results to modeling assumptions. If one can correct for
the dependent censoring that is present, then in theory survival curves estimated across trials under di↵erent
payment structures should be equivalent since they estimate the same, underlying, event model. As a result,
assuming that the censoring distributions di↵er across trials, even if dependent on event, one has the ability
to check for whether the correction for dependent censoring is done well. This is an advantage a↵orded by the
multiplicity of trials or sites within a trial, as dependence of censoring and event is generally not testable [19].
This result is a general one: if dependent censoring is present and survival curves are estimated under di↵erent
censoring models (all of which are associated with the event model) so that the estimated survival curves are
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all di↵erent, then correcting for the dependent censoring will give unbiased estimates of the survival curves
so that much less variation in those estimates should be observed. If we do not observe a decrease in the
variation of the survival curves across trials after weighting, we would know that weights were not calculated
e↵ectively. Our emphasis on payment structure and its possible e↵ect on inference would be unnecessary if
either it or dependent censoring were accounted for in analyses. However, a review of a variety of terms used
to describe dependent censoring in six major medical journals using PubMed and Google Scholar reveals
that it is often not discussed. Using these tools to search all available archives of the New England Journal
of Medicine (NEJM), Archives of Internal Medicine, Journal of the American Medical Association (JAMA),
Annals of Internal Medicine, Nature Medicine, and the Lancet with terms such as informative censoring,
dependent censoring, non-informative dropout, and permutations of them returned 65 total articles, with
NEJM, JAMA, and the Lancet each contributing approximately 15 articles to the total number. A review
of the articles showed that in some cases investigators did consider the possibility of informative censoring
being present in their studies and performed analyses under di↵erent modeling assumptions. In other cases,
investigators performed analyses that might have been less prone to violated assumptions. However, even if
all articles found appropriately addressed the possibility of informative censoring, it would still be a fraction
of all time-to-event analyses described in clinical journals.
Figure 17: Survival curves calculated under two di↵er-
ent incentive structures. There is significant variability
in the curves estimated under the di↵erent structures.
Figure 18: An inverse probability weighted analogue of
the Kaplan-Meier estimator gives less variable survival
curves under two di↵erent incentive structures.
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9 Conclusion
We have demonstrated that variation in compensation of research subjects may not only be unethical as
claimed in prior literature, but may also have substantial influence on statistical inference in clinical trials.
Through its influence on the censoring model of research subjects, di↵erent compensation patterns may result
in di↵erent censoring models and thus change inference if some degree of dependent censoring is present in
the trial. We have focused the context of this paper on clinical trials, but variation in compensation can a↵ect
observation studies as well. In that setting, di↵erent compensation structures would more influence which
populations are attracted to participate, though this point is relevant to clinical trials, too, as participant
demographics may vary with compensation, both at baseline and across time points in the trial. While
some might simply advocate for more compensation of research subjects so that there is a high percentage
of complete follow-up among participants, this suggestion is not feasible from both ethical and financial
standpoints. For consistency across clinical trials, standardization in compensation is essential. While
standardization is di cult to achieve both because incentives e↵ectiveness at increasing participant retention
is a function of participant values, demographics, socioeconomic status, and psychology, and not all incentives
are monetary, some greater degree of standardization is likely helpful to decrease censoring distribution
variability. However, even with standardized compensation, estimates of treatment e cacy are likely to be
biased in the presence of dependent censoring. Thus, use of statistical methods that correct for dependent
censoring and adjust for variable compensation structure when it is present should be emphasized more in
the clinical literature. We encourage clinical journals to mandate the application of these methods, along
with full disclosure of the compensation of subjects, caregivers, and investigators.
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